



LES RENCONTRES  
INTERNATIONALES  
DE *BIOTECHNOLOGIES*  
20**16**



## A brave new world for health innovation !

Building on the success of the first International Biotechnology Meeting that introduced 16 highly selected French biotechnology companies to 15 major worldwide pharmaceutical companies and many VCs last year, we decided to organize the second edition of this event. Indeed, we still strongly believe that tight links between biotech and pharma must be encouraged and strengthened, since therapeutic innovation will naturally flow from flourishing partnerships.

This second International Biotechnology Meeting is focused on neurological diseases, a therapeutic area with huge unmet medical needs despite important investments from pharmaceutical and biotechnology companies. However, there is some light at the end of the tunnel thanks to a better understanding of complex neurological disease mechanisms and new treatment strategies like those developed by the biotech here today.

These start-ups are at the forefront of innovation in neurological therapies and cast much light on the complementary nature of projects conducted by biotech and research and development undertaken by industrials.

French life science research and biotechs have yet demonstrated their potential and attractiveness towards international pharma and investors. This second International Biotechnology Meeting is the result of a growing ecosystem, the bio-side of the French Tech, fostering in the last years several unicorns and international leaders, yet to be multiplied.

A collaborative and modern scientific ecosystem could break the rules, with new ideas and technologies that have the potential to deliver real transformative changes and alternatives for the benefit of citizens.

That is our key ambition which in turn will ensure greater competitiveness for the French healthcare industry as a whole.

**Nicolas DUFOURCQ**  
General Manager BpiFrance

**bpi**france

**Philippe LAMOUREUX**  
General Manager Leem



## Objectif

Les collaborations entre petites sociétés de biotechnologies et grandes compagnies pharmaceutiques sont clés pour construire une industrie du médicament innovante et efficiente. Les petites sociétés de biotechnologies sont un vecteur majeur de l'innovation pharmaceutique.

Faire se rencontrer industriels internationaux et entreprises de biotechnologies est donc un enjeu hautement stratégique. C'est pourquoi les Entreprises du médicament (Leem), son Comité Biotechnologies et la Banque publique d'investissement (Bpifrance) se sont associés pour organiser les deuxièmes Rencontres Internationales de Biotechnologies (RIB).

### PERIMÈTRE

Cette deuxième édition des Rencontres Internationales de biotechnologies couvre la thématique choisie en 2016

### MALADIES NEUROLOGIQUES

#### Incluant

**Les thérapies géniques et cellulaires, les médicaments et leurs éventuelles technologies associées, les vaccins thérapeutiques mis au point pour traiter les tumeurs du cerveau, la sclérose en plaques, la maladie d'Alzheimer, la maladie de Parkinson, les maladies neurologiques rares, les migraines, les addictions, l'épilepsie à l'exclusion des maladies psychiatriques.**

### SÉLECTION

La sélection s'est effectuée en deux étapes successives : la première menée par les pôles de compétitivité Santé, Medicen Paris Région et Eurobiomed, la deuxième par un comité de sélection indépendant composé d'industriels, d'investisseurs et de chercheurs.

## Objective

Collaborations between small biotech companies and "big pharma" are today a vital key lever to stimulate in order to build up an innovative and efficient pharmaceutical industry. Those small companies represent a major vector of tomorrow's innovation.

It is therefore highly strategic to facilitate and stimulate interactions between biotech and industrial partners. In view of that innovation trend, the French Union of pharmaceutical industries (Leem), its Biotech Committee and the French public investment bank (Bpifrance) have joined together to launch the second International Biotech Meeting, between French biotech and pharmaceutical companies.

### SCOPE

This edition of the International Biotech Meeting covers, through presentations of selected French biotech companies, the following scope:

### NEUROLOGICAL DISEASES

**Gene and cellular therapies, medicines and their possible associated technologies, therapeutic vaccines designed for brain tumors, multiple sclerosis, epilepsy, Alzheimer disease, Parkinson disease, migraine, rare neurological diseases and addictions at the exclusion of psychiatric diseases.**

### SELECTION

The second International Biotech Meeting is grounded on a two-step selection process, conducted in the first phase by French health bioclusters, Medicen Paris Region and Eurobiomed, and in the second phase, by an independent scientific selection committee made up of industrials, investors and academics.

### Le Leem en quelques mots

Organisation professionnelle fédérant les entreprises du médicament, le Leem (Les Entreprises du Médicament) s'inscrit au cœur des grands enjeux de santé. Dans un contexte sans précédent de mutation scientifique et industrielle, il se mobilise, avec ses 260 adhérents et avec leurs 100 000 collaborateurs, pour promouvoir l'innovation et le progrès au service des patients, et pour renforcer l'excellence française en termes de recherche et de production. Promoteur de comportements responsables au sein du secteur, le Leem contribue, par une démarche de qualité, de sécurité et de transparence, à renforcer la confiance dans le médicament.

Le Comité Biotechnologies du Leem représente la composante biotechnologies de l'activité des entreprises du médicament réunies en France au sein du Leem. Il se positionne comme un think tank sur la recherche et l'innovation.

Il alimente dans ce cadre les réflexions du Leem par des études, des analyses et des propositions, avec une attention particulière donnée aux tendances en matière d'innovation dans le domaine des médicaments afin de développer l'attractivité de la France. Il est aussi à l'initiative de conférences grand public et de rencontres B to B entre grandes entreprises pharmaceutiques et sociétés de biotechnologies.

**Plus d'information sur : [www.leem.org](http://www.leem.org) - Twitter : @LeemFrance**

### Leem in a few words

Leem (Les Entreprises du Médicament) is the professional organization representing drug companies operating in France.

With a 100,000-strong workforce, these high-tech companies are striving to discover and develop drugs and vaccines to treat diseases. Their presence in 300 manufacturing and R&D sites throughout the country makes them key drivers of France's economic vitality.

Therapeutic innovation, drug safety, industrial and scientific attractiveness, economic efficiency and responsible practices are the core areas of its activity and commitment.

Aware of the innovative impact of biotechnologies in the health field, and wishing to take advantage of France's specific biosciences basis, Leem created the Leem Biotechnology Committee to help and promote the development of biotech activities in France.

**More info @ [www.leem.org](http://www.leem.org) - Twitter : @LeemFrance**

## Un guichet unique à l'initiative du Leem : le HUB PME

Les TPE/PME contribuent pour une large part au dynamisme du secteur de la santé : 45 % des entreprises ont moins de 200 salariés et emploient plus de 7 % des effectifs de l'industrie pharmaceutique.

Dans le foisonnement des sources d'informations et des offres de services sur internet, les TPE/PME ont du mal à obtenir des réponses claires aux questions concernant le développement de leur société : comment analyser mon marché ? Quels types de financement public demander ? Quels outils existent pour accompagner ma croissance ? Quel est le coût réel d'un salarié recruté ? Quelle réglementation d'un produit sous Autorisation Temporaire d'Utilisation ?...

Avec le Hub PME, les TPE/PME de la santé, qu'elles soient matures, en croissance ou tout juste créées, disposent désormais de réponses à l'ensemble des questions qu'elles se posent en termes de gestion, d'emploi, de réglementation ou de financement.

Ce nouvel outil imaginé par le Leem centralise plus de 130 questions et leurs réponses. Près de 10 partenaires se sont associés au Leem dans le cadre du hub, parmi lesquels Pôle emploi, la Banque Publique d'Investissement (BpiFrance), la Chambre de Commerce et d'Industrie (CCI), les pôles de compétitivité et l'Opca défi.



[www.hubpme.leem.org/](http://www.hubpme.leem.org/)

**Bpifrance**, filiale de la Caisse des Dépôts et de l'État, partenaire de confiance des entrepreneurs, accompagne les entreprises, de l'amorçage jusqu'à la cotation en bourse, en crédit, en garantie et en fonds propres. Bpifrance assure, en outre, des services d'accompagnement et de soutien renforcé à l'innovation, à la croissance externe et à l'export, en partenariat avec Business France et Coface. Bpifrance propose aux entreprises un continuum de financements à chaque étape clé de leur développement et une offre adaptée aux spécificités régionales.

Fort de 42 implantations régionales (90 % des décisions prises en région), Bpifrance constitue un outil de compétitivité économique au service des entrepreneurs. Bpifrance agit en appui des politiques publiques conduites par l'État et par les Régions pour répondre à trois objectifs :

- Accompagner la croissance des entreprises ;
- Préparer la compétitivité de demain ;
- Contribuer au développement d'un écosystème favorable à l'entrepreneuriat.

Avec Bpifrance, les entreprises bénéficient d'un interlocuteur puissant, proche et efficace, pour répondre à l'ensemble de leurs besoins de financement, d'innovation et d'investissement.

Plus d'information sur : [www.bpifrance.fr](http://www.bpifrance.fr) - <http://investissementsdavenir.bpifrance.fr/> -  
Twitter : @bpifrance

**Bpifrance**, a subsidiary of the French state and the Caisse des Dépôts and the entrepreneurs' trusted partner, finances businesses from the seed phase to IPO, through loans, guarantees and equity investments. Bpifrance also provides operational services and strong support for innovation, export, and external growth in partnership with Business France and Coface.

Bpifrance offers to businesses a large range of financing opportunities at each key step of their development, including offers adapted to regional specificities. With its 42 regional offices (90% of decisions are made locally), Bpifrance represents a strategic tool for economic competitiveness dedicated to entrepreneurs. Bpifrance acts as a back-up for initiatives driven by the French State and the Regions to tackle 3 goals:


- Contribute to SME's growth
- Preparing tomorrow's competitiveness
- Contributing to the development of a positive entrepreneur ecosystem.

With Bpifrance, businesses benefit from a powerful, efficient and close representative, to answer all their needs in terms of financing, innovation and investment.

More info @ [www.bpifrance.fr](http://www.bpifrance.fr) - Follow us on Twitter : @bpifrance

## Les actions de Bpifrance dans le secteur de la Santé en 2015

339 M€ alloués aux domaines **Pharma/Bio-industrie & Technologies Médicales**





#### À propos de Medicen Paris Region – [www.medicen.org](http://www.medicen.org)

Labellisé en 2005, Medicen Paris Region est un pôle de compétitivité mondial mobilisant entreprises, organismes académiques de recherche publique et d'enseignement supérieur et collectivités territoriales autour d'une même ambition : donner à l'Ile-de-France la place de leader européen au plan industriel, dans les domaines de la santé du futur – médecine personnalisée et de précision – selon les principaux axes : la biotechnologie, les technologies médicales et le numérique.

Fort de plus de 240 membres, sa mission est d'accélérer le développement des PME innovantes en les accompagnant dans leur activité économique et leur stratégie à l'international ; de faciliter la mise en relation des acteurs de l'innovation en Ile-de-France ; de valoriser la région Ile-de-France comme usine à produits à la conquête des marchés internationaux et de renforcer la visibilité et la compétitivité d'un écosystème représentant à lui tout seul plus de 50% des Life Sciences en France.

Animateur et catalyseur de cet écosystème, il travaille avec les acteurs régionaux et nationaux de l'innovation en santé. Depuis la création du pôle, 281 projets ont été labellisés et financés par l'Etat (Fonds Unique Interministériel), bpiFrance/ISI, l'ANR, le FEDER, le Grand Emprunt et/ou par les collectivités territoriales / la Région Ile-de-France pour un investissement total de 1,2 milliards € et 527 millions € d'aides publiques et 49 nouveaux produits commercialisés dans les domaines de l'imagerie des dispositifs médicaux et des outils biologiques.

#### About Medicen Paris Region – [www.medicen.org](http://www.medicen.org)

One of Europe's largest cluster in Life Sciences and Healthcare and your best gateway to access European biotechnologies markets.

Our mission is to highlight and reinforce the Paris Region as Europe's leading industrial center for medical devices innovations and health technologies. With over 240 members, our goal is to increase the attractiveness of the Paris region, to strengthen the international competitiveness of the health sector and to develop the economic growth of our members in strategic markets through collaborative innovation.

Since the cluster was created in 2005, 281 R&D projects have been accredited and funded by the French State and local authorities, for a total project budget of €1,2 billion and €527 millions of public subsidies.

**EUROBIOMED est l'accélérateur du développement de la filière santé, depuis la recherche fondamentale jusqu'au marché, au bénéfice des patients et de l'économie du sud de la France.** Fondé en 2009 par l'ensemble des acteurs de la filière santé des régions Provence Alpes Côte d'Azur et Languedoc-Roussillon, EUROBIOMED pointe au sommet des classements européens à toutes les étapes de la chaîne de l'innovation : enseignement, recherche fondamentale, translationnelle et clinique, centres d'innovation technologique, start-ups et success stories industrielles.

Ensemble, les 253 membres du collectif EUROBIOMED (dont 200 entreprises) constituent non seulement un formidable moteur de développement régional (165 projets de R&D représentant 650 millions d'euros d'investissements et 700 emplois directs) mais aussi une source de solutions pour les millions de patients confrontés à des pathologies sévères : cancers, pathologies inflammatoires chroniques, maladies infectieuses, maladies (ré)émergentes, maladies neurologiques, maladies rares et orphelines. EUROBIOMED offre des ressources et propose des solutions dédiées aux sociétés et aux organismes de recherche de la filière santé pour les aider à innover, à se financer, à se développer et à atteindre leurs objectifs stratégiques et commerciaux pour, in fine, améliorer la prise en charge et la vie des patients.

**Développer la filière sur le sud de la France :** *Animation et mise en réseau des membres, Renforcement de l'écosystème, Développement de collaborations nationales et internationales, Représentation de la filière vis-à-vis de tous les tiers (pouvoir publics, international), Mise en œuvre d'événements scientifiques et business.*

**Structurer et accompagner le financement de projets public-privé/de R&D :** *Veille sur les appels à projets, Identification de partenaires, Accompagnement au montage et au financement du projet, Suivi de projet jusqu'à la commercialisation*

**Proposer un accompagnement personnalisé aux entreprises :** *Analyse stratégique ; Financement – Aide à la levée de fonds ; Développement commercial et international ; Stratégie règlementaire ; Industrialisation et production*

Eurobiomed est présidé par Xavier Tabary, et dirigé par Emilie Royere

**EUROBIOMED is the catalyst of the health sector in the Provence-Alpes-Côte d'Azur and Languedoc-Roussillon regions. We provide resources and initiatives to help life science companies achieve their business goals and improve life through innovations in health.**

Founded in 2009 by regional stakeholders, EUROBIOMED tops European rankings in all stages of innovation: education, basic research, translational and clinical research, technological innovation centers, start-ups and manufacturing.

Together, the 253 EUROBIOMED members from 200 different companies are a driving force in regional development (with 165 projects, representing 650 million EUR of investment and 700 direct jobs) and a source of solutions for millions of patients coping with serious conditions such as cancer, chronic inflammatory disease, infectious and (re)emerging diseases, neurological diseases, and rare diseases.

EUROBIOMED provides resources and offers solutions for businesses and research organisations in the health sector to help them innovate, finance, develop and achieve their strategic and business objectives to ultimately improve the treatment and the lives of patients.

Mission and Activities :

**Develop the sector in the South of France :** *networking of members, Representation of the sector to third parties (public authorities, international), Implementation of scientific and business events*

**Structuring and financing of public-private R&D projects :** *Monitoring calls for projects, Identification of partners, Support for project formation and financing, Project follow-up to marketing*

**Personalised support for businesses :** *Strategic analysis, Financing – Fundraising, Commercial development and internationalisation, Regulatory compliance*

## Sommaire / Table of contents

Programme / Program 15

Le comité de sélection / Selection committee 16 -19

Les sociétés de biotechnologies  
Biotech companies

Les entreprises du médicament  
Pharmaceutical companies

ACTICOR	p.22	ABBVIE	p.40
AELIS FARMA	p.23	BIOGEN	p.41
ALZ PROTECT	p.24	BOEHRINGER-INGELHEIM	p.42
B&A THERAPEUTICS	p.25	CLEVEXEL PHARMA	p.42-43
BIODOL	p.26	GSK	p.44
BRAINEVER	p.27	IPSEN	p.45 - 47
BRAINVECTIS	p.28	LILLY	p.47 - 50
GECKO	p.29	MERCK	p.50 - 52
MEDDAY	p.30	MSD FRANCE	p.52 - 53
ONCODESIGN	p.31	NOVARTIS VENTURE FUNDS	p.53
QYNAPSE	p.32	PFIZER	p.54 - 56
SURICOG	p.33	ROCHE	p.58 - 60
THERANEXUS	p.34	SANOFI	p.60 - 62
VECT-HORUS	p.35		
VFP THERAPIES	p.36		

## Programme / Program

10:00 Ouverture / Opening

10:15 - 11:00 **Première session / First session**

*Modérateur / Moderator: Pierre-Henri Longeray*

- BRAINVECTIS
- ACTICOR
- ALZ PROTECT

11:00 - 11:50 **Deuxième session / Second session**

*Modérateur / Moderator: Manuel Gea*

- B&A Therapeutics
- GECKO
- QYNAPSE
- MEDDAY

11:50 - 12:10 Pause café / Coffee break

12:10 - 13:00 **Troisième session / Third session**

*Modérateur / Moderator: Sylvain Forget*

- VECT-HORUS
- ONCODESIGN
- AELIS FARMA
- BRAINEVER

13:00 - 14:00 Déjeuner / Lunch break

14:00 - 18:00 Rencontres B to B / B to B meetings



**Pierre-Henri LONGERAY**

*President of Biopharma activities of Merck in France*

He is Doctor in Pharmacy and in the pharmaceutical industry since 1986, He joined the Market Research team at Lipha (Lipha became part of the Merck Group in 1991) and has worked during his career with Merck in several positions : General Manager in Belgium, President of Theramex in Monaco, the division of Merck specialising in Women's Health, Responsible Pharmacist for Merck Sante. And President of the Biopharma activities of Merck in France.



**Manuel GEA**

*is a serial entrepreneur & business angel developing disruptive innovations in the life sciences, digital, healthcare sectors.*

Manuel Gea is the Co-founder & CEO Bio-Modeling Systems, the world's first Mechanisms-based Medicine company. Created in 2004, profitable since 2006, thanks to its recurrent clients, its patented collaborative discoveries already led to:

1. A world's first in neurodegenerative diseases with CEA: 2 awards in the US & Europe
2. Pherecydes-Pharma: BMSsystems' spin-off, MR infections therapies, world's first clinical trial with phages in Phase I/II,
3. Theranexus: CEA Life Sciences' spin-off exploiting CEA/BMSsystems' copatent WO/2010/029131, in CNS therapies, successful Phase I, Phase II entry.

He is graduated from Ecole Centrale Paris, and has a sociology of organizations degree from Paris IX Dauphine University.



**Sylvain FORGET**

*Founding partner BlueDil et CEO Nassyane*

Sylvain Forget is a recognized expert of the pharmaceutical environment. For 25 years Sylvain did set up and managed domestic and international operational organizations with a focus on niche and orphan products, serving as Sales Director, Business Unit Director, European Marketing Director, General Manager and VP, in Europe, Middle-East and North Africa.

Sylvain is also associate Professor of Paris-Sud Pharmacy University and the President of the Pedagogic Comity of the Pharmaceutical Marketing Master where he leads the coaching and personal development program.

Since November 2015, Sylvain is President of BlueDil SAS, a French consulting company dedicated to support companies and organizations willing to bring solutions to people suffering from severe and orphan diseases. BlueDil syndicates a network of independent consulting companies. Based in Paris, BlueDil operates internationally and conducts a wide range of strategic and operational missions.



## Le comité de sélection Selection committee

Les sociétés de biotechnologies ont été sélectionnées à la fois sur leur thématique de recherche, l'excellence de leur projet et leur volonté de nouer des alliances avec des entreprises pharmaceutiques.

Un comité de sélection mixte et indépendant a évalué les sociétés candidates sur la base de leurs dossiers et de leurs présentations orales.

Biotech companies have been selected on the basis of their research area, their scientific excellence and their will to forge collaborations with big pharmaceutical companies.

A joint independent committee has proceeded to their evaluation, based both on their written and oral presentations.



**Yves AGID**  
*Directeur scientifique de l'ICM*

Yves Agid is a neurologist and a neuroscientist. He held different positions in Pitié Salpêtrière University Hospital in Paris : Chairman of the Federation of Neurology, Coordinator of the Clinical Investigation Center, Chairman of the Institute of Neurology. He successively directed the Inserm U289 laboratory ("Mechanisms and Consequences of Neuronal Death"), the Institute of Neurosciences and the "Pathophysiology of basal ganglia disorders" team (Inserm U679).

He is a Founding Member and scientific director of the Brain & Spine Institute (ICM). He received numerous distinctions, the Alice Wilson Award in Parkinson's disease, USA, 1993, the Grand Prix Inserm de la Recherche Médicale, 2001, the ISI Thomson Award, 2005 (most cited French neuroscientist in the last 20 years), the C. David Marsden Lectureship Award, Movement Disorder Society, 2010, the John Penney Memorial Lecture, Massachusetts General Hospital, 2012 and the Drucker Memorial Lecture, Beeth Israel Diaconess Medical Center, 2012.



**Benoit BARTEAU**  
*Chargé d'investissement, Bpifrance*

Benoit BARTEAU joined Bpifrance Investissement in 2014 as Investment Manager in the Innobio fund and the fund for Innovative Biotherapies and Rare Diseases. He brings over 7 years of biotech experience in various positions. In 2007, as a scientist, he joined the start-up In-Cell-Art where he co-discovered a vaccine candidate against hepatocellular carcinoma (liver cancer), developed an antibody production service and was co-author of 9 scientific articles.

In 2010, he's been in charge of the scientific and business development of the company and was involved in the regulatory pre-clinical development of a vaccine candidate and developed antibody sales, contributing to the significant growth the company over the period. Benoit holds a Master Degree in Biotechnology Engineering from the University of Technology of Compiègne (UTC), a PhD in immunology from the University of Nantes and an executive Master in Finance from IAE Paris.



**Pascale AUGÉ**  
*Présidente du directoire d'Inserm transfert*

Before joining Inserm Transfert, Pascale had led Institut Pasteur's Technology Transfer and Entrepreneurship office since 2011. She has more than 15 years' experience in the fields of technological innovation in life science and health technology, research transfer and entrepreneurship, and the biotechnology start-up industry. She headed business development at Neurotech, Entomed and AB Science then operational strategy in the sciences and health technology, and ran Ernst & Young activities in France. She also chaired the evaluation committee reviewing "high-market-potential products, technologies or services" at France's Agence Nationale de la Recherche from 2008 to 2011.

Pascale Augé holds a doctorate in molecular pharmacology, experimental pharmacology and metabolism from Université Paris V, and a chemical engineering degree from the Ecole de Chimie de Strasbourg.



**Marion CASSAU**  
*Manager, Bpifrance Le Hub*

After one year in the Innovation Task Force of the European Medicines Agency in London, Marion joined Bpifrance - the French Public Investment Bank - in 2011. She financed and followed more than 100 French startups in Life Sciences, IT and Healthcare.

In 2015, she joined Bpifrance Le Hub, a new activity within Bpifrance aiming at catalyzing partnerships and corporate investments between large corporations, SMEs and startups.

Marion is particularly focused on sourcing relevant startups for selected corporate customers, and setting up the first interactions.



**Marie-Pierre CHEVALIER**  
Directrice des Alliances Stratégiques, Pfizer

As Strategic Alliances Director at Pfizer France since 2009, Marie-Pierre Chevalier is responsible for identifying potential partners within the French R&D landscape of excellence. The objective is to develop sustainable Research Partnerships in France with Academic Institutions or Biotech companies for research projects fitting well with Pfizer strategic research needs.

She has more than 20 years of experience in Pharmaceutical industry; working for 12 years in the field of Oncology and served in various positions included Clinical Research, Medical Affairs, Strategy & Business Development. She joined Pfizer in 2003 as Business Development manager, leading the Oncology portfolio management.

She graduated as Doctor in Medicine and held a Master degree in Management at the University Pierre & Marie Curie, Paris.

She is currently member of the Strategic Committee of InnoBio fund (Public-Private VC funds in Health and life Science), member of the Scientific Advisory Board of Inserm Transfert Initiative (Seed funds), member of the Selection Committee of iPEPS (incubator of the Brain Institute –ICM at Paris Pitié-Salpêtrière Hospital) and member of the Executive Committee at ARIIS (National Alliance for Research and Innovation in Health Industries).



**Patrice DENËFLE**  
Directeur de l'Institut Roche

Patrice P. Denëfle, Ph.D HDR and Associate Professor at Paris-Descartes, has pioneered the field of gene therapy, and has initiated multiple programs in Human genetics, functional genomics and Onco-pharmacogenomics at Rhône-Poulenc Rorer than Sanofi-Aventis.

After 3 years as CSO and head of translational R&D at Genethon, he joined Ipsen in 2010 as Senior VP, Digital and Translational Sciences, to build and run a global platform fully integrated Medical and Scientific approaches to Precision Medicine. He founded MedBiomiX Partners SAS in 2014. He was appointed VP, Head of the Institut Roche in January 2015.



**Christian DELEUZE**  
Président de Sanofi Genzyme

Christian Deleuze is currently the President of Sanofi Genzyme France and Genzyme Polyclonals, part of the Sanofi Group. He joined the company in 2010 and leads the company's strategic planning in line with the global Sanofi Genzyme mission, ensuring patients are provided with treatments, driven by cutting-edge science and a commitment to treating unmet medical needs in Rare Diseases, Multiple Sclerosis and recently Oncology and Immunology.

He obtained his medical degree from, Lariboisière Saint-Louis in Paris and graduated from the ESSEC Business & Management School in the early 90's. He began his professional pharmaceutical career at Bayer Pharma, and from there went on to hold different positions at Searl, Pharmacia and Pfizer where he was Marketing Director and responsible for the launch of Celebrex, in charge of strategy and tactics for branding and global positioning.

In 2003 he created the French subsidiary of Sankyo Pharma, which became Daiichi Sankyo France. In his role as President and founder, from 2003 to 2010, he positioned France as the European leader for the Japanese group, with 500 employees.

Today Christian is also President of the Rare Disease Committee at the LEEM (the French pharma syndicate), where he sits on the board and is a member of both the Administration Committee and the Biotechnology Committee. The LEEM Rare disease group unites the rare disease community; pharmaceutical companies, association representatives and health institutions dedicated to the orphan disease cause.

Sanofi Genzyme exists in France since 1994 and counts over 400 employees in total. The headquarters are situated in Saint Germain en Laye (78), with teams throughout the French regions including activities in French overseas territories and in Lyon at the Polyclonal bioproduction site. The plant is in the Gerland district in Lyon, the world renowned biotech cluster. The site produces polyclonal antibodies preventing organ rejection in transplanted patients. This product is exclusively produced by Sanofi Genzyme in Lyon and is available in 68 countries worldwide.



**Chahra LOUAFI**  
Directrice d'investissements, Bpifrance

Chahra Louafi is Senior Investment Director and Head of the Biotherapies and Rare Diseases Fund of Bpifrance (formerly CDC Entreprises). Before joining CDC Entreprises in 2001, Chahra Louafi was in charge of project development and company creation for a private incubator that specialised in biotechnologies. She is Chairman of the Supervisory Board of Inserm Transfert Initiative and member of the Supervisory Board of Cap Decisif Management.

She has invested in and is on the board of DBV Technologies – which went public on Euronext Paris and on Nasdaq, Eyevenys, Sensorion – which went public on Alternext, MedDay Pharmaceuticals, Pixium Vision – which went public on Euronext Paris, Lysogene, Annapurna Therapeutics - which was successfully sold to Avalanche Biotechnologies, BrainEver, Enyo Pharma, Gecko Biomedical, GMP-Orphan, Sparingvision and Therachon.



**Stéphane PALFI**  
Neurochirurgien, CHU Henri Mondor

Stéphane Palfi, MD.,PhD, is a Professor of Neurosurgery and Head of the Neurosurgery Department at Henri Mondor Medical center, Paris University (UPEC) and Head of a research Team 14 INSERM IMRB 955.

His interests are in developmental therapeutics for Parkinson disease, Huntington disease, Tremor, Dystonia, Psychiatric disorders. He has worked extensively in the area of electrical neuromodulation of the brain in movement disorders, gene therapy for Parkinson disease, cell grafting for Huntington and Parkinson disease as well as primate models of neurodegenerative disorders. Pr. Stéphane Palfi has published extensively on trophic factor and enzymes based gene therapy in Parkinson disease and Huntington disease. He is a principal investigator on numerous preclinical and clinical studies and has been involved in studies of many novel agents including implanted brain devices, trophic factors GDNF, CNTF and Lentiviral vectors Prosovin.



**Annick SCHWEBIG**  
Présidente d'Actelion France (2000-2015) et du Comité Biotechnologies du Leem (2000-2016)

Annick Schwebig joined Actelion in 2000. Her primary task, as General Manager of Actelion Pharmaceuticals France, was to set up and develop the French affiliate. Prior to that, Annick Schwebig held various positions of increasing importance within Bristol-Myers Squibb where she was Vice-President for Research & Development in Europe from 1993 to 2000.

Her other responsibilities include:

- Vice-President of the non-governmental organization "Equilibres & Populations"
- Member of the Paris Ile de France Chamber of Commerce and Industry
- Member of experts committee « funds large venture » within BPI France (a Public Investment Bank)
- Collectis Administrator
- Board of Trustees Member of the ESSEC Business School
- Vice-President of the Inserm strategic council



**Marc PESCHANSKI**  
Directeur scientifique, I-STEM

Marc Peschanski is currently the scientific director of the Institute for Stem cell Therapy and Exploration of Monogenic diseases (I-STEM, INSERM/UEVE associated to the AFM-Téléthon) in Evry (Paris district).

Hired as a Research Associate at INSERM in 1982, he had obtained previously a MD and a PhD from the University of Paris, the latter on the neurophysiology of pain. He did a post-doctoral training at UC San Francisco. He built his first own team on pain relay neurons in the thalamus, that he analyzed using physiological and anatomical approaches.

From 1985 on, he has changed topics and undertaken in parallel basic research dealing with brain neuroplasticity and pre-clinical studies aiming at using those newly described capacity of adult neurons for therapeutic purposes with fetal neural grafts. In 1991, he moved to the Hospital Henri-Mondor in Créteil to start a translational research INSERM unit that carried out clinical trials of fetal neural grafts (then gene therapy) in patients with Parkinson's and Huntington's disease. Positive results of the latter clinical trial in a disease which has no other known treatment, has led to the organisation of a multi-centre European-wide phase II trial.

Since 2005, he has started a new venture by creating the first and largest Institute for stem cell research in France, I-STEM, dedicated to the exploration of therapeutic potentials of pluripotent stem cells in rare diseases of genetic origin. I-STEM currently comprises more than 75 people in 10 research teams interested in neurological diseases, myopathies, retinopathies and genodermatoses. He has been one of the founders of NECTAR, the Network for European CNS Transplantation And Restoration, and its first chairman (1991-92) and coordinated since several European networks on gene therapy (NeuroGeT), Huntington's disease (StemHD) and the use of stem cells for toxicology (SCR&Tox). He has founded the Clinical Investigation Centre in Créteil in 2001 and coordinated its activity until 2006.



**Rafaèle TORDJMAN**  
Managing Partner, Sofinnova Partners

Rafaèle Tordjman, MD, PhD, is a Managing Partner. She joined Sofinnova Partners in 2001. Prior to this, she worked as a research scientist at the Institut National de la Recherche Médicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post doctoral fellowship in immunology.

Rafaèle obtained her medical degree and her specialisation in Haematology and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the "Young Manager Program" at INSEAD (France, in 2002). She has invested in and is on the board of Ascendis [ASC], DBV technologies [DVB] – which went public on Euronext Paris and on Nasdaq, Nucana Biomed, MedDay, ObsEva, Lysogene and Enyo Pharma.

She was also on the board of Corevalve, Endoart before it was successfully sold to Allergan Inc, of Pregel before the latter was successfully sold to Gedeon Richter, HBI Ltd before being acquired by Meda and of Flexion Therapeutics – which went public on Nasdaq.



**Les sociétés  
de biotechnologies**

---

**Biotech companies**



## Acticor Biotech

*Company name:* **ACTICOR Biotech**  
*CEO:* **Gilles AVENARD**  
*Phone:* **+33 (0)6 09 16 68 50**  
*Mail:* **gilles.avenard@acticor-biotech.com**  
*Company location:* **Paris, France**  
*Area of expertise:* **Drug development**

### Company description

Acticor Biotech is a spin-off of Inserm founded in 2013, dedicated to developing innovative treatments in the therapy of acute ischemic stroke. Acticor Biotech's CEO, Dr Gilles Avenard, is founder and former CEO of Onxeo, a Euronext® company. The goal is to conduct phase 2a in ischemic stroke with a fragment of MoAb in order to be "first in class" antithrombotic drug without bleeding risk. The company is virtual, "one asset" and it works with consultants and sub-contractors.

### Know-how and technological competences

Acticor is developing ACT-017 a Humanized antibody (Fab). The therapeutic candidate is in pre-clinical stage of development with the aim to enter into clinical phase 1 in 2018 and phase 2a in 2019. The drug is positioned as a first-line anti-thrombotic treatment, to be combined or not with thrombolysis or mechanical thrombectomy, in the therapy of acute ischemic stroke. The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI) which is involved in the growth of the thrombus and not in physiological hemostasis.

### Ongoing partnerships

INSERM U1148 – Laboratory for Vascular Translational Science – Bichat Hospital – Paris - France.  
 Catalent Biologics for GPEX® cell line use - Madison, WI 53717- United States.  
 Merck Millipore for pharmaceutical development and manufacturing - Martillac – France.

### Further partnerships sought

The main goal is to demonstrate an improvement of a clinical score at 3 months in a phase 2a in combination with thrombolysis. The company is looking for Industrial partnerships worldwide to pursue the development after phase 2a, register and market the product in Ischemic Stroke.



## AELIS FARMA

*Company name:* **AELIS FARMA**  
*CEO:* **Valérie SCAPPATICCI**  
*Phone:* **+33 (0)5 57 57 37 70**  
*Mail:* **v.scappaticci@aelisfarma.com**  
*Company location:* **Bordeaux, France**  
*Area of expertise:* **Addiction**

### Company description

Aelis Farma is a clinical stage biotech company, conducting research and development on innovative, first in class, signaling specific drugs targeting the CB1 receptor. Our first therapeutic target is cannabis abuse: our lead compound, AEF0117 has completed preclinical development, showing exceptional preclinical efficacy, ADMET and CMC profiles. It will go first in man in Q4 2016. Since the CB1 receptor is involved in a large number of diseases, other therapeutic applications for the company's compounds include Down syndrome, autism (Fragile X Syndrome), metabolic disorders and skin diseases.

### Know-how and technological competences

The NCE developed by Aelis Farma, are the first pharmacological compounds able to specifically inhibit only one of the signaling pathways activated by the stimulation of a G-proteins coupled receptors (GPCR), the CB1 receptor. Thanks to these very selective cellular effects, our compounds antagonize most behavioral effects of Cannabis active principle THC but have none of the adverse effect of CB1 full agonists. Our compounds are fully protected thanks to composition of matter and method of use patent requests filed in all major countries.

### Ongoing partnerships

- The company works in close collaboration with the Bordeaux Institut Magendie Inserm Neurocenter where its offices are located: it benefits from the expertise of the Center's pluri-disciplinary teams to consolidate its pre-clinical proofs of concept and broaden the understanding of SSis mechanism of action.
- Aelis Farma, in collaboration with Columbia University, has been awarded a grant by the US National Institute on Drug Abuse to finance its phase 1 and 2a clinical studies.

### Further partnerships sought

Aelis Farma is preparing its Round A in order to finance the clinical proof of concept of its lead compound AEF0117 for cannabis use disorders, and to develop the company's application portfolio beyond cannabis addiction, targeting most specifically Down syndrome with AEF0117. Aelis Farma is also actively seeking partnering opportunities with selected industry partners specialized in CNS.



*Company name:* **ALZPROTECT**  
*CEO:* **Philippe VERWAERDE**  
*Phone:* **+33 (0)03 28 55 50 51**  
*Mail:* **contact@alzprotect.com**  
*Company location:* **Loos, France**  
*Area of expertise:* **Biotechnology, R&D**

### Company description

AlzProtect's mission is to develop new bioactive molecules for the treatment of neurodegenerative diseases up to the first clinical trial in patients and partner with/license to a pharmaceutical company for further development and marketing. Our molecules have innovative modes of action. They are suitable for the treatment of tauopathies including well known Alzheimer's disease (AD) and orphan disease Progressive Supranuclear Palsy (PSP).

### Know-how and technological competences

AZP2006 is an orally available drug candidate developed to act on the main physiopathological hallmarks of Alzheimer's disease and related tauopathies such as PSP. AZP2006 is not positioned as a symptomatic treatment, it aims at slowing down the disease progression. In 2015, we performed the first clinical trials on healthy volunteers. Our goal is to rapidly set up a first Phase 2 study on PSP patients in order to demonstrate the biological effects of AZP2006 on the central nervous system.

### Further partnerships sought

We are looking for an industrial partner that could help us finance our clinical development and Target exploitation.



**B&A Therapeutics**

*Company name:* **B&A Therapeutics**  
*CEO:* **Yehezkel BEN-ARI**  
*Phone:* **+33 (0)4 91 82 81 42**  
*Mail:* **yehezkel.ben-ari@inserm.fr**  
*Company location:* **Inmed (Mediterranean Institute of Neurobiology), Marseille, France**  
*Area of expertise:* **Neurobiology - drug development - repositioning**

### Company description

B&A Therapeutics, a biopharmaceutical company founded by Dr. Ben-Ari in 2014, develops an innovative therapeutic approach to improve Parkinson disease treatment: a non-dopaminergic drug complementary to standard treatments which acts on motor symptoms like gait and freezing reducing their severity with little side effects. After the success of a pilot study in 4 patients, B&A Therapeutics will set up a phase II clinical trial to confirm the efficacy and tolerance of the molecule.

### Know-how and technological competences

B&A Therapeutics has completed the proof of concept in animal models and patients with Parkinson disease (pilot study on 4 patients; Damier P et al., 2016), and has determined the mechanism of action of the drug. It has the internal capacity to conduct phase II clinical studies in compliance with the European guidelines. Indeed, it has developed a strong network with experienced service providers and clinicians.

### Ongoing partnerships

B&A Therapeutics is involved in a number of collaborations with:

- researchers from the Mediterranean Institute of Neurobiology (Inmed) for fundamental research,
- clinicians, specialists in Parkinson disease treatment, like Pr. Philippe Damier and Pr. Jean-Christophe Corvol for clinical research,
- experts in formulation, regulatory affairs, statistics and clinical study management.

### Further partnerships sought

B&A Therapeutics is seeking for investors to finance a phase II study on patients with Parkinson disease (60 patients will be recruited in 8 centers in France) and confirm the efficacy and tolerance of the treatment.



**BIODOL**  
THERAPEUTICS

*Company name:* **BIODOL THERAPEUTICS**

*CEO:* **Fabien GRANIER**

*Phone:* **+33 (0)6 24 34 42 94**

*Mail:* **frevah@genethon.fr**

*Company location:* **Montpellier, France**

*Area of expertise:* **Pain, Neuropathic Pain**

### Company description

Biodol Therapeutics aims at developing first-in-class compounds as innovative drugs for the treatment of chronic neuropathic pain (NP). Biodol Therapeutics has identified and got exclusive patent rights on the FLT3 receptor as a controller of the NP state. The preclinical and clinical development of intra- or extracellular FLT3 inhibitors is a strategic proprietary approach of the company.

### Know-how and technological competences

Biodol Therapeutics accumulated a series of experimental evidences showing that the activation of the FLT3 receptor is the main NP trigger and responsible for NP maintenance. Results highlight a previously unknown key role for that master hub protein in a new mechanism by which NP is specifically generated. Innovative treatments can be designed and implemented to reverse NP without affecting normal nervous system functioning.

### Ongoing partnerships

Biodol Therapeutics is a spin-off from academic research (INSERM, University of Montpellier, University of Strasbourg, CNRS). Our work is performed in collaboration with the teams of 2 inventors: LIT (« Laboratoire d'Innovation Thérapeutique » in Strasbourg – Didier Rognan) for the synthesis of new chemical entities and INM (Institute of Neurosciences of Montpellier – Jean Valmier) for in vitro and in vivo validation of the newly synthesized molecules. The management is composed of highly experienced people in the field of pharmaceutical development and business.

### Further partnerships sought

BIODOL Therapeutics' aim is to out-license its complementary programs (intra- and extracellular strategies) at the end of phases I/II clinical trials to pharmaceutical groups able to run late stage clinical development so as to market our innovative NP treatments. The company is currently looking to raise funds to support the preclinical and early stage developments as well as to collaborate on technology co-development.



**Brain**  
**Ever**

*Company name:* **BRAINEVER**

*CEO:* **Bernard GILLY**

*Phone:* **+33 (0)6 08 75 45 71**

*Mail:* **bgilly@ibionext.com**

*Company location:* **Paris, France**

### Company description

BrainEver is a disruptive biotechnology company created in 2015 to develop novel therapeutic approaches for the treatment of neurodegenerative disorders.

### Know-how and technological competences

BrainEver's unique approach is derived from the work of Pr. Alain Prochiantz at College de France and a collaboration with Pr. Takao Hensch at Harvard Medical School (USA). Its platform is based on the use of specific proprietary homeoproteins to permanently modify the physiology and metabolism of surviving neurons. The administration of this breakthrough treatment aims to induce a steady improvement of clinical status and a reduction of behavioral or memory deficits.

### Ongoing partnerships

Non-human trials are ongoing to further validate the approach targeting the treatment of Parkinson's disease, Rett Syndrome, ALS and Huntington Disease. The preclinical work on Parkinson disease (monkeys) is performed by Motac and Pr Kordower at Rush University.

### Further partnerships sought

1. Equity investment in the next round of financing
2. Potential partnership (TBD)



*Company name:* **BRAINVECTIS**

*CEO:* **Jérôme BECQUART**

*Phone:* **+33 (0)6 07 47 70 56**

*Mail:* **jerome.becquart@brainvectis.com**

*Company location:* **Paris, France**

*Area of expertise:* **Pharmaceutical R&D, gene therapy, neurodegenerative diseases**

### Company description

BrainVectis aims to be a platform to develop gene therapy treatments for several neurodegenerative diseases by restoring brain cholesterol metabolism. We develop an innovative treatment for Huntington's disease and Alzheimer's disease based on administration of a vector, AAV, genetically modified to transfer the gene (cDNA) for the enzyme CYP46A1 into the human brain. BrainVectis will conduct the preclinical studies and the initial clinical trials until proof of concept for the vector has been established in the two neurodegenerative diseases.

### Know-how and technological competences

We have developed expertise in the use of gene therapy vectors, particularly adeno-associated viruses (AAV) for the treatment of neurodegenerative diseases. We have also developed knowledge in the metabolism of cholesterol in the brain (our target). Nathalie Cartier has gained expertise in the transfer of gene therapy treatment to the clinic as she is involved in two clinical trials ongoing in the treatment of childhood leukodystrophies.

### Ongoing partnerships

CEA/MIRCen for primate studies, gene therapy and imaging platform. BrainVectis labs are located in MIRCen. Atlantic Gene Therapy, Nantes: INSERM UMR1089, Philippe Moullier's group, including the process development group.

### Further partnerships sought

- BRAINVECTIS is willing to collaborate on product developments : we seek partners for preclinical and clinical development steps.
- BRAINVECTIS is also looking to raise funds in 2017 to finance its preclinical development program.



*Company name:* **Gecko Biomedical**

*CEO:* **Christophe BANCEL**

*Phone:* **+33 (0)1 76 21 72 28**

*Mail:* **cbancel@geckobiomedical.com**

*Company location:* **Paris, France**

*Area of expertise:* **Medical Devices and Localized Drug Delivery**

### Company description

Gecko Biomedical is a privately owned medical device company based in Paris - France, dedicated to the rapid development and the commercialization of polymers, namely in the form of sealants and adhesives, that support tissue healing. Gecko's polymers are non-toxic, bind to tissues and deliver wound closure within the wet dynamic environments in the body. Gecko is currently expanding its polymer in the field of localized drug delivery, namely in the context of brain tumors. Gecko Biomedical's intellectual property pillars are well grounded around innovations developed and protected by the M.I.T.

### Know-how and technological competences

PGSA Gecko Biomedical's proprietary polymer is a photocurable resin, initially developed as sealant indicated as adjunct to standard methods to achieve hemostasis in vascular surgery. It consists in a viscous liquid pre-polymer that quickly polymerizes, becoming solid, upon exposure to light. We are currently working in expanding the range of application of our polymer in new indications, including its use in localized drug delivery.

### Ongoing partnerships

- A set of academic and industrial partners have been identified and ongoing work is being conducted to validate the platform in localized
- Collaboration with GlioTex (Institut du Cerveau et de la Moelle Epinière), aiming to evaluate the use Gecko polymers in the context of glioblastoma therapy.
  - Collaboration with the laboratory of Pr. Philippe Menasché (Hôpital européen Georges-Pompidou), aiming to evaluate the use of Gecko polymers in the context of heart disease.

### Further partnerships sought

Gecko's core expertise is in polymer formulation design. To complement this expertise, and accelerate the development of the platform, Gecko is looking to establish partnerships with key players with expertise in molecules that can benefit from localized delivery to achieve stronger therapeutic benefits.



*Company name:* : **MEDDAY PHARMACEUTICALS SA**

*CEO:* **Frédéric SEDEL**

*Phone:* **+33 (0)1 81 51 66 71**

*Mail:* **frederic.sedel@medday-pharma.com**

*Company location:* **Paris, France**

*Area of expertise:* **Biotechnology**

### Company description

MedDay is a privately held biotechnology company developing new drugs targeting brain metabolism to treat severe diseases of the nervous system. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer); and Guillaume Brion, MD (Chief Operating Officer). The Company's most advanced pipeline candidate, MD1003, as succeeded in phase 3 for the treatment of primary and secondary progressive multiple sclerosis. MD1003 is currently available for patients under an early access program in some European Countries ('cohort ATU' in France).

### Know-how and technological competences

Three molecules are currently in development: MD1003 in primary and secondary progressive multiple sclerosis (MS) and in X-linked adrenoleukodystrophy; MD1103 in autism spectrum disorders and MD1105 in Alzheimer's disease. In addition, the SPECMET metabolomics platform screens cerebrospinal fluid (CSF) from patients with CNS disorders to identify metabolic pathways that are disrupted. The goal of this approach is to identify approved or shelved compounds that are known to target the aberrant pathway.

### Ongoing partnerships

The company has ongoing collaborations with the following institutions: Assistance Publique Hôpitaux de Paris (France), Commissariat à l'Energie Atomique (France), Brain&Spinal cord institute (France), Mayo Clinic (USA), McGill University (Canada), Cleveland Clinic (USA), Institut d'investigació Biomedica de Bellvitge (IDIBELL, Barcelona), University of Edinburgh (UK).

### Further partnerships sought

The company is currently pursuing its own development with the goal of becoming a fully integrated pharmaceutical company. The company might be interested in commercial partnership for a limited period of time and restricted geographic areas. Medday is looking for acquiring new opportunities in the field of neurometabolism.



*Company name:* **ONCODESIGN SA**

*CEO:* **Philippe GENNE**

*Phone:* **+33 (0)3 80 78 82 60**

*Mail:* **pgenne@oncodesign.com**

*Company location:* **Dijon, France**

*Area of expertise:* **Biotechnology**

### Company description

Oncodesign has a mixed business model: its Experimentation Department works as a CRO and markets a broad range of products and services for the assessment, validation, targeting and diagnostic linking of anticancer therapies, while its Discovery Department develops its own drugs in oncology and outside oncology (Parkinson's disease, Crohn's disease, Alzheimer's disease).

### Know-how and technological competences

The Experimentation activity is organized in three technological platforms: PREDICT® (conventional in vitro and in vivo pharmacology); Chi-Mice® (in vivo chimeric humanized models) and PharmImage® (multimodal, non-invasive pharmacology-imaging). Oncodesign's discovery activity is based on the Nanocyclix® technology which generates potent, selective and brain penetrant macrocyclic kinase inhibitors. Oncodesign has solid expertise in the optimization of these compounds towards clinical candidates.

### Ongoing partnerships

Oncodesign Discovery Department (DD) is co-developing kinase inhibitors programs with IPSEN, UCB, BMS (see Oncodesign website)... Other programs developed by DD involve numerous collaborators from different background (academic, institutes, pharmaceutical companies). In regard to the CK1 delta program, existing collaborations include EATRIS web, Pr. P. Scheltens (Director of Alzheimer Centre, Amsterdam), Wiep Scheper (Amsterdam University), Jeroen J.M. Hoozemans (Amsterdam University) and Mario Salmons (Mario Negri Institute, Milan).

### Further partnerships sought

Oncodesign has discovered selective and potent CK1 delta inhibitors. CK1 delta represents an opportunity to treat patients with early Alzheimer's Disease (AD). Our expertise in pharmacology-imaging also opens an opportunity to develop a PET-tracer for early AD diagnosis. We are looking for a partner with expertise in developing drugs in neurological disorders. Our partner would support the program from the lead optimization phase.





*Company name:* **QYNAPSE**  
*CSO:* **Olivier COURREGES**  
*Phone:* **+33 (0)6 29 41 22 52**  
*Mail :* **ocourreges@qynapse.com**  
*Company location:* **Paris, France**  
*Area of expertise:* **Medical device**

### Company description

QYNAPSE is a medical device company that provides innovative technology to measure drug efficacy and predict clinical outcome of CNS diseases. We help pharmaceutical companies, neurologists, radiologists and imaging experts make the most of medical images by automatically quantifying a wide range of imaging biomarkers and combining them with other medical data for evidence-based decisions.

### Know-how and technological competences

QYNAPSE is a spin-off company of the french neuroimaging platform « CATI » (9M EUR grant, 2010) which has supported over 25 Research projects. The team of founders combines extensive expertise in multi-modal image processing, raw data and post-processing quality control, medical device development, human-computer interaction and 3D visualization, design and management of clinical studies, neuro-imaging and clinical data statistical analysis as well as customer-driven innovation in the pharmaceutical industry.

### Ongoing partnerships

QYNAPSE collaborates with leading research centers in the field of MRI/nuclear image processing and statistical data analysis, including NeuroSpin (CEA), ARAMIS (Institut du Cerveau et de la Moëlle épinière ICM - CNRS), CENIR (ICM/UPMC/INSERM/CNRS/APHP), LIB (UPMC) and ISPED (Bordeaux University - INSERM), as well as 3 clinical centers in France (CHU Pitié-Salpêtrière, CHU Bordeaux & Hospices Civils de Lyon), 1 in the US (Brigham and Women's hospital) and 1 in Canada (Douglas Hospital)

### Further partnerships sought

We are seeking collaboration opportunities with pharmaceutical/biotech companies to validate the predictive value of Qynapse algorithms for multiple sclerosis and Alzheimer therapies (trials already conducted or ongoing).



*Company name:* **SURICOG**  
*CEO:* **Marc MASSONNEAU**  
*Phone:* **+33 (0)1 40 60 70 60**  
*Mail:* **mm@suricog.com**  
*Company location:* **Paris, France**

### Company description

Suricog provides embedded eye tracking hardware and software solutions to address all features of human vision within the digital world. Suricog recently acquired E(ye)Brain company which develops eye tracking as medical devices to assist practitioners in the early diagnosis of neurological, psychiatric diseases and reading disorders by analyzing ocular movements.

### Know-how and technological competences

These are medical devices using video-oculography or eye-tracking with the goal of analysing the brain's functional structures and activity. It provides assistance in the diagnosis of neurological and psychiatric diseases by recording eye movements, and producing high valued and quantitative neuromarkers.

### Ongoing partnerships

Suricog has developed a strong network of private and public partners within more than ten countries worldwide including UCSF, Singapore Hospital, Pitié-Salpêtrière Hospital in Paris.

### Further partnerships sought

Based on its constant improvement in terms of easy-repeatable, non-invasive, highly efficient in-depth neurological device, SuriCog is looking for deepening its use among the pharmaceutical world, in the aim of earlier and more precise detection of therapeutic effects on most of the targeted neuro-diseases.



*Company name:* **THERANEXUS S.A.**  
*CEO:* **Franck MOUTHON**  
*Phone:* **+33 (0)1 46 54 79 86**  
*Mail :* **franck.mouthon@theranexus.com**  
*Company location:* **Lyon, France**  
*Area of expertise:* **Laboratoire pharmaceutique**

### Company description

Theranexus offers an innovative and smart approach to tackle unmet medical needs in the CNS therapeutic area. The company has developed a proprietary screening technology which led to the identification of proprietary combinations of two marketed drugs, one being a standard of care in the indication while the other modulates glial intercellular connections through connexins made gap junctions (also known as nexus) in the CNS.

### Know-how and technological competences

- proprietary combinations with a differentiating mechanism of action;
- best-in-class candidates, i.e. with higher efficacy;
- dramatically decreased risks / costs / time to market;
- an answer to unmet needs in the challenging area of neurology;
- a versatile technology delivering both proprietary programs and opportunities for R&D partnerships to offer lifecycle management or program rescue options.

### Ongoing partnerships

- Christian Giaume, PhD Inserm unit U840
- Michel Hamon, PhD - Pierre and Marie Curie University.
- Yves Dauvilliers, MD, PhD – CHRU Montpellier / Inserm unit U1061

### Further partnerships sought

Theranexus' management and board of directors are open to looking at the full range of strategic options which could support the future development of its projects in the long-term.



*Company name:* **VECT-HORUS**  
*CEO:* **Alexandre TOKAY**  
*Phone:* **+33 (0)6 30 40 36 95**  
*Mail :* **alexandre.tokay@vect-horus.com**  
*Company location:* **Marseille, France**  
*Area of expertise:* **Biotechnology (Drug delivery)**

### Company description

VECT-HORUS designs and develops peptide-based vectors that facilitate the delivery of drugs or imaging agents into organs, notably into the brain, and to tumors. The vectors target receptors involved in "Receptor Mediated Transport" (RMT). By combining drugs or imaging agents to its vectors, VECT-HORUS allows them to cross biological barriers that restrict access to their target, notably the blood-brain barrier (BBB).

### Know-how and technological competences

The Company has developed a great deal of expertise on the LDL receptor, which has allowed the discovery, validation and optimization of several vector families with different properties. These proprietary vectors are short peptides, most of them cyclic, and have been protected by several patents.

The vectors can be conjugated to different classes of therapeutic (conventional drugs, proteins, antibodies, oligos, etc.) or imaging agents. VECT-HORUS has demonstrated the proof-of-concept of its technology in various animal models.

### Ongoing partnerships

The Company has signed three collaborations with industrial partners :

- SANOFI: The transport of a therapeutic antibody for the treatment of neurodegenerative diseases
- SERVIER: The transport of a peptide to the brain to treat an undisclosed brain disease.
- ADVANCED ACCELERATOR APPLICATIONS : innovative nuclear/molecular conjugates for CNS imaging

The Company collaborates also with various academic labs (INSERM, CNRS, etc).

### Further partnerships sought

- VECT-HORUS mission is to make its highly innovative platform technology available to pharmaceutical and biotech partners to transport their drugs to the brain and other organs.
- The Company is also building a pipeline of proprietary drug candidates and imaging agents that are available for licensing-out.



*Company name:* **VFP Therapies**  
*CEO:* **Francis MARSAIS**  
*Phone:* **+33 (0)6 80 32 57 64**  
*Mail :* **contact@vfp-therapies.com**  
*Company location:* **Rouen, France**  
*Area of expertise:* **Pharmacy**

### Company description

VFP Therapies is a biopharmaceutical company located in Rouen (Normandy) at the forefront of research and development focusing on Brain Diseases.

With a benefit of hindsight over the last 10 years, the VFP Therapies approach brings an innovative response to minimize the noxious side-effects of drugs as well as to overcome the Blood-Brain-Barrier crossing issue. The R&D studies have already demonstrated the technical proof of its concept in initial in vitro and in vivo models for the symptomatic treatment of Alzheimer's Disease.

### Know-how and technological competences

The innovative approach of VFP Therapies relies on the concept of Bioprecursor which does not present any biological activity before being transformed into their active form. Due to the corresponding oxidative biochemical pathway this transformation has been proven to selectively occurring inside the brain. VFP Therapies Bioprecursors are thus much safer brain targeting molecules than any classical prodrug or encapsulated API.

### Ongoing partnerships

The development strategy of the company is based on a strong intellectual property covering preliminary academic research performed prior to the foundation of VFP Therapies which have resulted in getting two patents (W02006/103120 and PCT/EP13305088 - VFP Therapies owns 100% of the 1st patent and 70% of the 2nd one with an exclusive license to operate).

### Further partnerships sought

- VFP Therapies is currently seeking for collaboration to initiate co-developments focusing on two major axes:
- Research and Development of lead candidates in Alzheimer Disease (AD) up to phase I/II to provide them in license to Big Pharmaceutical Companies.
  - Technology extended to other families of drugs for the treatment of Brain diseases. The VFP Therapies technological platform will lead to partnerships with pharmaceutical industry.



**Les entreprises  
du médicament**

---

**Pharmaceutical  
companies**



**Company name: AbbVie**  
**Headquarters: Chicago - USA**  
**Company size: 28 000 employees**  
**Annual sales 2015: 23 billion dollars**  
**R&D Staff: 6500**  
**R&D investment: 4.4 billion dollars**  
**R&D investment: 5 billion dollars**

## COMPANY DESCRIPTION

AbbVie is a highly focused, research-driven biopharmaceutical company.

It takes a global leader to deliver patient-centered solutions around the world. We uniquely combine the assets and capabilities of an experienced pharmaceutical company with the flexibility and focus of a biotech to pursue the most meaningful opportunities for patients. The result is a biopharmaceutical company that offers new approaches to addressing today's health issues — from life-threatening illness to chronic conditions.

We target specific difficult-to-cure diseases where we can leverage our core research and development (R&D) expertise to advance science and create solutions that go beyond treating the illness to have a positive impact on patients' lives, as well as on economies, societies, and science itself. We look at problems holistically.

## HISTORY OF COMMITMENT

In neurology area, AbbVie has been committed for over 15 years to healthcare professionals and patients.

AbbVie priority is to contribute to improve knowledge, develop tools and make them available to healthcare professionals, to optimize patient care, improving their quality of life.

## PRODUCT PORTFOLIO IN THE AREA

We launched a Parkinson's disease (PD) treatment, levodopa-carbidopa intestinal gel, committed to both treatment.

and scientific innovation for Parkinson's disease patients. PD is a progressive disorder of the brain that leads to shaking (tremors) and difficulty with walking, movement and coordination. A lack of dopamine in the brain results in abnormal nerve functioning, causing a loss in the ability to control body movements. PD is the second most common neurological disorder worldwide after Alzheimer's disease.

In 2016, AbbVie and Biogen offer an alternative approach, daclizumab, to treat multiple sclerosis (MS). AbbVie and Biogen co-promote daclizumab in the United States. Outside the United States, Biogen is responsible for commercialization.

## PROSPECTIVE IN THE AREA : THEMATIC PRIORITIES

Our current innovative research focuses on compounds that have the potential to treat a variety of chronic disabling neurological conditions. We have several compounds in the early and advanced investigational phases for diseases such as Alzheimer's disease, Parkinson's disease, progressive paraspinal nucleus palsy, spinal cord injury and multiple sclerosis — all of which affect millions of people worldwide.



**Marie-Sophie BEHIER**  
 Medical Manager Neuroscience

### Training and academic background

Medical Doctor (Faculté de Médecine d'Amiens) – General Practitioner.

Diploma in Statistical Methodology in Clinical Research and Epidemiology (STARC & STEP - Faculté de Médecine Kremlin-Bicêtre).

Diploma in Critical lecture and interpretation of clinical trials (Faculté de Médecine de Lyon).

### Professional experience – industry background

More than 20 years in pharmaceutical industry, mainly dedicated to Clinical Research and Medical Affairs at the affiliate level through 5 companies (Schering, Pharmacia, Lundbeck, Novartis and AbbVie).

Main domain of experience is Neuroscience with expertise acquired and developed in different diseases as multiple sclerosis, Parkinson's disease, Alzheimer's disease or schizophrenia.

Overall missions : contribution to the development plan of compounds (phase II and III), design and follow-up of local studies (including Health Authorities-required studies), coordination of medical activities (studies, publications, medical communication in congresses and symposia), implementation of national and international Advisory Boards with key external experts.

**Specific activities :** introduction on market of drugs approved in multiple sclerosis (interferon beta-1b in 1995, fingolimod in 2010), Alzheimer's disease (memantine) and Parkinson's disease (rasagiline).

### Contact

Marie-Sophie BEHIER  
 AbbVie France - Medical Department 10, rue d'Arcueil 94150 RUNGIS  
 Tel. 1 : +33 1 45 60 82 32  
 Mail : marie-sophie.behier@abbvie.com



**Company name: Biogen**  
**Headquarters: Cambridge USA**  
**Company size: 7 000**  
**Annual sales 2014: \$10.8 billion**  
**R&D investment: 20% annual revenues reinvested**  
**Net income: +24% increase in GAAP earnings per share 2014**

## COMPANY DESCRIPTION

One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of neurology research with a pipeline of potential groundbreaking medicines for conditions including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). The company is also focused on developing therapies for rare genetic disorders and high-quality biosimilars for autoimmune conditions.

Led by world-class research and development, Biogen uses novel science and leading-edge technologies to discover, develop, commercialize, and manufacture transformative therapies for patients with few or no treatments options. Our global organization is committed to a single mission: to make a meaningful difference in the lives of patients suffering from devastating medical conditions.

## HISTORY OF COMMITMENT

Founded in 1978 by 2 Nobel prizewinners we are one of the world's oldest independent companies. For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is focused on revolutionary new MS treatments with the goal of reversing even repairing damage by the disease.

## PRODUCT PORTFOLIO IN THE AREA

Biogen has the leading portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of

neurology research with a pipeline of potential groundbreaking medicines for conditions including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).

## R&D FOCUS PORTFOLIO AND PROSPECTIVE IN THIS AREA :

We are applying our neurological expertise to solve some of the most challenging and complex diseases of the brain, and we have one of the largest pipelines of mid-and late-stage candidates for the treatment of Alzheimer's disease. As we enter a transformative period in neurology, Biogen is driving a deeper understanding of disease biology and developing life-changing treatments for the millions of people suffering from these conditions.

As we uncover new insight into human biology, Biogen is employing cutting-edge technologies to disorder potential treatments for rare and genetic disorders. These include our efforts to create potentially life-changing therapies for infants and children with SMA; relieve the debilitating impact of trigeminal neuralgia, a form of neuropathic pain; and explore entirely new ways to treat a range of diseases through gene therapy.

## PLACES OF WORLDWIDE INVESTIGATIONS :

Biogen is currently running 140 clinical trials on 19 drug candidates.



**Alfred W. SANDROCK, jr.**  
 M.D., Ph.D.

Alfred W. Sandroock, Jr. is Biogen's Executive Vice President, Neurology Discovery & Development Center, Neurodegeneration Therapeutic Area and Chief Medical Officer and has served in this position since November 2015. Dr. Sandroock has served as Group Senior Vice President from May 2014 to October 2015 as well as Chief Medical Officer since February 2012. Since joining us in 1998, Dr. Sandroock has held several senior executive positions, including Senior Vice President of Development Sciences, Senior Vice

President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandroock received his B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.



**Spyros ARTAVANIS-TSAKONAS**  
 Executive Vice President and Chief Scientific Officer at Biogen

Spyros Artavanis-Tsakonas is Executive Vice President and Chief Scientific Officer at Biogen, and has served in this position since March 2016. Dr. Artavanis-Tsakonas joined Biogen in May 2013 as Senior Vice President and Chief Scientific Officer.

In 1998, Dr. Artavanis-Tsakonas joined the Harvard Faculty as Professor of Cell Biology at the Harvard Medical School, where, since 2015, he continues his affiliation as a Professor Emeritus of Cell Biology. From 1999 to 2007, Spyros was the K.J. Isselbacher-P. Schwartz Professor at the Massachusetts General Hospital Cancer Center, and is the founding Director of the Developmental and Regenerative Biology Program at Harvard Medical School. During 1983-1998, Dr. Artavanis-Tsakonas was at Yale, where his most recent appointment was as Professor of the Departments of Cell Biology and Biology, and a Howard Hughes Medical Institute Investigator.

Spyros also served as the Director of the Biological Sciences Division at Yale. In 1999, he was elected Professor at the Collège de France, holding the Chair of Biology and Genetics of Development. Since 2012, Dr. Artavanis-Tsakonas is Professeur honoraire at the same institution, and he is also the Founding Director (2007-2009) of the Department of Genetics and Developmental Biology at the Institut Curie, Paris. Dr. Artavanis-Tsakonas is a co-founder of Exelixis Pharmaceuticals, Inc., Cellzome (acquired by GlaxoSmithKline in 2012), and Anadys Pharmaceuticals, Inc. (acquired by Hoffman-La Roche in 2011). He is also President and co-founder of Fondation Santé.



Company name: **Boehringer Ingelheim**

Company size: **47,500 employees**

Number of countries: **145**

Annual sales 2014: **2015 14.8 billion euros**

R&D investment: **20.3% of its net sales**

Net income: **1,577**

## COMPANY DESCRIPTION

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees.

## HISTORY OF COMMITMENT

The pharmaceutical company Boehringer Ingelheim was founded in 1885 by Albert Boehringer (1861-1939) in Ingelheim am Rhein. From its beginnings in 1885 when it employed just 28 people in Nieder-Ingelheim, the company has since become a global enterprise.

## PRODUCT PORTFOLIO IN THE AREA

The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

## PROSPECTIVE IN THE AREA : THEMATIC PRIORITIES

As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.

## Places of Worldwide Investigations

- Biberach, Germany
- Ridgefield, USA
- Laval, Canada
- Vienna, Austria
- Kawanishi, Japan
- Reims, France
- Buenos Aires, Argentina
- Milan, Italia



**Lucilla MANSUY**

Head of Clinical Research Unit  
Boehringer-Ingelheim France

### Higher Education

Medical Degree-1980.  
Degree in Oncology-1983.  
Degree in Psycho-Pharmacology-1997.

### School Graduation

Thesis for Medical Doctor Degree-1980.

### Title and Responsibilities

#### 2015 - current

Boehringer Ingelheim France, Head of Clinical Research Unit.

#### 2004-2015

Pierre Fabre, Head of Clinical Development ( CNS/Oncology).

#### 2003-2004

Sanofi-Aventis, Thrombosis Head Therapeutic Area.

#### 1999-2003

HMR - Aventis France, Clinical projects Leader (Oncology /Thrombosis/ CNS).

#### 1996-2003

Rhone-Poulenc Rorer Corporate, Oncology Clinical Projects Leader.

#### 1981 -1996

IGR Villejuif-Paris, Resident in Oncology.



Company name: **CLEVEXEL Pharma**

Company size: **46 employees**

Number of countries: **na**

Annual sales 2014: **na**

R&D Staff: **38**

## COMPANY DESCRIPTION

Founded in 2013, CleveXel Pharma has a team of 38 scientists that select molecules with substantial potential, optimize them and develop them through to proof of concept in humans with the aim of licensing them out to major players in the pharmaceutical industry.

## HISTORY OF COMMITMENT TO RARE DISEASES

Active Member of ARIIS Committee & of the RIR Program since their inception.

CleveXel Pharma is an expert in diseases of the central nervous system with a unique positioning in France. Specializing in Parkinson's disease, the Company is currently developing two first-in-class drug candidates that use innovative therapeutic approaches to overcome the limitations of current drug treatments and thus improve the quality of life of patients with Parkinson's.

## PRODUCT PORTFOLIO IN THE AREA

- 2 Actives R&D PROGRAMS : two first-in-class drug candidates in Parkinson's disease

## PROSPECTIVE IN THE AREA : THEMATIC PRIORITIES

- two first-in-class drug candidates in Parkinson's disease



**Laurent BENEL**

Life Sciences CSO

### Profil

30 years of experience in R&D, Manufacturing and Regulatory affairs: Cephalon Development Center, Lafon Laboratory.

15 peer-reviewed articles and publications, numerous speeches.

Contribution to the development of the Modiodal® and Provigil® psychostimulants (marketed in the US).

Characterization of armodafinil, active ingredient of Nuvigil®.

PhD in Pharmaceutical Sciences.

### Training and academic background

Doctorat (Ph D) in Pharmaceutical Sciences from Université Paris Sud & Ecole Pratique des Hautes Etudes Cellular and molecular biologist by training with a strong background in cell culture and cellular pharmacology. Complementary training in project management, team management, metrology, computer system validation, ISO-9001, GAMP, GLP.

### Industry background

#### 2013 - Present

Co-founder & Senior Director, Life Sciences CLEVEXEL Pharma Expertise in the field of CNS & ONCOLOGY: Life Sciences/Clinical Research/Pharmaceutical Development/Quality.

#### 2010 - 2013

Associate Director, Validation and Metrology CEPHALON, France.

#### 2001 - 2010

In charge of the completion of renovation project for the Development Center (in absence of site director). Associate Director, Validation, Logistics and Support Department Senior Manager, Validation and GxP Support Department Head of Oncology Research Department CEPHALON, France.

#### 1995 - 2001

Head of Inflammation Biology Department Laboratoire LAFON, France.

#### 2001 - 1992

Senior Researcher, Pharmacokinetics & Metabolism Department Contract researcher, Cellular Toxicology unit (implanted at Faculty of Pharmacy in Paris) Laboratoire LAFON, France.

### Contact

Laurent BENEL

19, avenue du Professeur Cadiot 94700 Maisons-Alfort Cedex France

Tel. 1 : +33 1 79 84 19 35

Mobile : +33 6 85 04 04 92

Mail : laurent.benel@clevexel.com



**Christian BLOY**

President

### Profil

30 years of experience in R&D, Manufacturing and Regulatory affairs: Cephalon Inc., Genzyme, Flamel Technology, Cassenne Laboratory (Hoechst Marion Roussel Group).

More than 35 peer-reviewed articles and 6 patents, including one on the Central Nervous System, Numerous speeches at international congresses.

PhD in Immunohematology & Discoverer of naftazone.

### Training and academic background

6 years of fondamental research in Hematology and Cellular Biology.

Collaboration with English and American laboratories. 30 years of Pre-clinical development and Manufacturing Technical Support. Elaboration and following up of quality control and manufacturing optimization development plans. Elaboration and following up of pre-clinical development plans. Creation and follow up of an experts' group. Management of a Development center. 1991: Post-doctoral training course in the P. Agre's laboratory (John Hopkins Hospital, Baltimore,

USA). Peter Agre, Nobel Price of Chemistry in 2003. 1990: Doctorat (Ph.D.), Immunology, University of Paris VI, France. 1986: Diplôme d'Etude et de Recherche en Biologie humaine (DERBH), Immunohematology, University of Paris VI, France. 1985: C.E.S. Immunology, University of Paris VI, France. 1984: Master degree in Biochemistry and Immunology University of Paris VI, France.

### Industry background

#### 2013 - Present

CLEVEXEL Pharma CEO & Founder Expertise in the field of CNS & ONCOLOGY : Lifes Sciences/Clinical Research/Pharmaceutical Development/Quality.

#### 2013 - 2010

CEPHALON EUROPE / TEVA Site Manager & Senior Director Europe Drug Development / Member of European executive committee.

#### 2002 - 2010

GENZYME CORPORATE : Senior Director, Research & Development / Member of senior sciences committee : Immune Mediated Diseases / Transplant. GENZYME POLYCLONALS S.A.S : Senior Director of Technical Services / Member of senior executive committee. GENZYME POLYCLONALS S.A.S : Director of Research and Development / Member of executive committee.

#### 1998 - 2002

FLAMEL TECHNOLOGIES Direction of Pre-Clinical Development / Member of management committee.

#### 1992 - 1998

CASSENNE LABORATORY (HOECHST MARION ROUSSEL group) Pre-Clinical Department Manager. CASSENNE LABORATORY Head of Pre-Clinical Vascular Development : Development of pharmaceutical molecules to support the medical marketing department (publications, action mechanisms) & to define new therapeutic directions.

#### 1986 - 1992

INSTITUT NATIONAL DE TRANSFUSION SANGUINE Engineer, Head of project in J.P./ Cartron's Laboratory.

### Contact

Christian BLOY

19, avenue du Professeur Cadiot 94700 Maisons-Alfort Cedex France

Tel. 1 : +33 1 79 84 19 35

Mobile : +33 6 80 59 59 11

Mail : christian.bloy@clevexel.com



Company name: **GlaxoSmithKline**

Company size: **96 500 employees**

Number of countries: **115**

Annual sales 2015: **32,8 billion euros**

R&D Staff: **14 000**

R&D investment: **4 billion euros**

## COMPANY DESCRIPTION

We are a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world, helping them to do more, feel better and live longer.

We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare. Research is vitally important to the success of our business. We are one of the few healthcare companies researching medicines and vaccines for the World Health Organisation's three priority diseases - HIV/AIDS, tuberculosis and malaria.

## HISTORY OF COMMITMENT

The GSK NeuroSciences Therapeutic Area Unit (NSTAU) strategy is to make valuable innovative medicines available to patients that make a difference to their quality of life and the lives of those that care for them.

In Neurodegenerative diseases the strategic focus of the Neurodegenerative Discovery performance Unit is to slow or halt the progression of diseases, in particular Alzheimer's disease and Parkinson's disease.

To do this, beyond symptomatic management options, we need to better understand the science behind the diseases, to identify and prosecute targets with high human confidence in rationale and also be able to employ therapeutically sensitive measures that can detect changes in the earliest stages of clinical

development that will ultimately have a real significant effect on patients clinical presentation and their daily activities.

The Neuroexcitation Discovery Performance Unit mission is to discover and develop medicines for the treatment of neuroexcitatory diseases such as pain, epilepsy and other neurological diseases, which still has a huge unmet need.

There are many dedicated scientists working in the field of neurosciences in a variety of companies and organizations and it makes sense that by sharing resources and ideas the science can progress faster, with greater confidence and on a much larger scale than working in isolation.

Public Private Partnerships therefore offer GSK a collaborative way forward to tap into a world of resources to complement our own expertise and help find new solutions to understand and treat diseases. In this spirit, the Neuro VPoC team (Virtual Proof of concept) has been established to scout breakthrough science by establishing an effective network and collaborations.

## PRODUCT PORTFOLIO IN THE AREA

The NSTAU currently has a commercial portfolio in Epilepsy, Parkinson Disease and Depression, and a pipeline of early stage medicines in Parkinson Disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, and pain.

## R&D FOCUS PORTFOLIO AND PROSPECTIVE IN THIS AREA

As part of efforts to help as many patients as possible with neurologic disorders, the NSTAU will continue working with the internal discovery and early development units and also review and examine external opportunities for collaborations.



**Nadine WEISSLINGER-DARMON**

*Medical Director Specialty Products, Clinical Research & Academic Alliances. GSK France*

### Training and academic background

MD degree from the medical school ( University of Nancy / France).  
University diplomas in clinical pharmacology, Infectious diseases and Nutrition.

### Industry background :

1992-1997: Cardiovascular medical project leader (Rhône-Poulenc-Rorer).

1997-2000: International Cardiovascular medical director (Aventis).

2000-2005: Cardiovascular and Anesthesia medical Director (AstraZeneca).

Since 2005@ GSK : Therapeutic Area medical director (HIV & infectious diseases, then cardio-vascular, metabolic, neurosciences & rare diseases) and currently Medical Director Specialty Products, Clinical Research and Academic Alliances.

### Areas of interest :

Translational, Early & Late phase Clinical Research (Metabolic, Immuno-inflammation & infectious diseases, rare diseases, neurosciences and oncology).

Public-Private Partnerships.



Company name: **IPSEN**

Company size: **4 500 employees**

R&D staff: **900 employees**

Annual sales 2015: **€ 1.4 billion**

[www.ipсен.com](http://www.ipсен.com)

## COMPANY DESCRIPTION

Ipsen is a global specialty-driven pharmaceutical company committed to the treatment of targeted debilitating diseases. Its development strategy is supported by three franchises: neurology, endocrinology and urology-oncology. Ipsen also has a significant presence in primary care. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2015, R&D expenditure totaled close to €193 million, representing close to 13% of Group sales.

The Group has an active policy of partnerships. Indeed, since its inception, Ipsen has consistently implemented an open Research and Development strategy to nurture its own innovation capacities. These networks are built around Ipsen's areas of expertise in endocrinology, neurology and oncology. The goals of these partnerships are to strengthen Ipsen's R&D innovation capacity, notably by giving access to new and promising technologies and support the exploration of new research fields. Therefore, the Group has strategically established its R&D sites in geographical proximity with highly regarded university research centres, enabling the teams to access the best science & innovation:

i) The Research and Development Centre at Les Ulis (France) is close to Paris-Saclay campus. The scientists are focused on drug discovery of novel medicines in the fields of neurology and oncology.

ii) The Research and Development Center newly established in Cambridge (Massachusetts,

United States) reinforces its leadership in the field of peptides and its open-innovation strategy with proximity of world-class academic centers and biotechs.

iii) The Research Center in Oxford (UK) is focused on the discovery of new modified recombinant botulinum toxins, mainly for neurology indications.

## HISTORY OF COMMITMENT

Ipsen's mission, "innovation for patient care", highlights the Group's determination to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. Focusing on patients is critical to determine unmet medical needs and identify both the pathophysiological mechanisms and biological targets that should be developed.

In neurology, while not working in psychiatric disorders, the Group is a key player in the treatment of movement disorders (spasticity, dystonia, dyskinesia...). Ipsen is committed to improving the mobility, autonomy and quality of life of patients with these very disabling motor disorders. In this field, The Group's commitment to developing neurotoxins dates back more than twenty years. The acquisition in 2013 of Ipsen Bioinnovation (formerly Syntaxin), a leader in the engineering of recombinant toxins, allows Ipsen access to innovative technologies and to develop a complete portfolio of toxins. Those efforts to develop new Botulinum toxins with improved properties are associated with prospects for new formulations and delivery approaches of toxins to better respond to patients needs. Ipsen also develops small molecules programs in Parkinsonism and Huntington's disease, neurodegenerative diseases presenting as well movement disorders.

In addition to movement disorders, Ipsen advances programs for pain and neurogenic bladder overactivity.

## PRODUCT PORTFOLIO IN THE AREA OF NEUROSCIENCES

**Dysport®**: is based on botulinum toxin 'Type A', a compound based on a bacterium that inhibits the transmission of nerve impulses to the muscle. Botulinum toxin injections cause contracted muscles to relax, enabling patients to return to a number of their daily activities, while

relieving them and improving their quality of life. Dysport® presents a diverse range of drug indications:

- Spasticity (exaggerated muscular tone following a stroke for example). For example, Dysport® was recently approved by FDA for injection for the treatment of Lower Limb Spasticity in children aged two and older
- Cervical dystonia (a chronic condition in which the neck is deviated),
- Hemifacial spasm (a movement disorder characterized by contractions of the muscles located on one side of the face that can lead to disfigurement),
- Blepharospasm (involuntary contraction of the eyelids).

## R&D FOCUS PORTFOLIO AND PROSPECTIVE IN THIS AREA

**BN82451B (Phase IIa)** – this molecule is currently in clinical development in Huntington's disease and has completed a phase I clinical pharmacology trial. A Phase IIa clinical proof of concept of BN 82451B in Huntington Disease patients is currently underway in Germany. This molecule is simultaneously able to exert multiple pharmacological activities and is designed to protect the mitochondria.

**VSN16R (Phase IIa)**: VSN16R is a novel, orally active small molecule compound developed by Canbex Therapeutics Ltd (Canbex) and intended for the treatment of spasticity in Multiple Sclerosis and other disorders. Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. In February 2015, Ipsen and Canbex announced that Canbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of VSN16R.

**LRRK2 kinase inhibitors (Pre-clinical phase)** – Ipsen has entered in 2012 into a research collaboration with Oncodesign to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against genetic forms of Parkinson's Disease.

## PLACES OF WORLDWIDE INVESTIGATIONS

Worldwide.



### Christophe THURIEAU

Sr VP Global Scientific Affairs & President Ipsen Innovation

#### Training and academic background

##### 1987-1989

Pre and post doctoral fellow, Harvard Medical School, Boston (USA).

##### 1986-1988

Ph.D., University Pierre and Marie Curie, Paris, France.

#### Industry background

##### 2010-Present

Sr VP Global Scientific Affairs and Strategic Sourcing & President Ipsen Innovation.

##### 2007-2009

VP Translational Research and President Ipsen Innovation.

##### 2002-2007

VP Research, Ipsen group.

##### 2000-2001

Research Director, Ipsen group.

##### 1997-2000

Senior Director New Discovery Technologies, Ipsen group.

##### 1989-1996

Laboratory Head, Servier laboratories.

#### Areas of research interest

Oncology, Neurology, Endocrinology, Biology and chemistry technology platforms.

#### Contact

Christophe THURIEAU  
Address: Ipsen Innovation, ZI de Courtaboeuf,  
5 avenue du Canada, 91940 Les Ulis, France  
Tel.1: +33 1 60 92 20 07  
Tel. 2: +33 1 60 92 20 31  
Mail: christophe.thurieu@ipsen.com



### Pierre-Etienne CHABRIER

Vice President Scientific Affairs Neurology at IPSEN

#### Training and academic background

Docteur "es Sciences".

Post-doctoral fellow at the Imperial College in London (UK).

Training in chemistry and pharmacology in CNRS and Pasteur Institute (France).

#### Industry background

##### 2010-Present

Vice President Scientific Affairs Neurology / IPSEN.

##### 1982

Pierre-Etienne joined Ipsen in 1982 to set up a Molecular Pharmacology unit before becoming Head of Biology research.

Leading various research programs in neurology, oncology, inflammation and cardiovascular system, he was notably involved in the study of endothelial vasoactive substances and their role in cerebrovascular disorders.

In the field of neurology, he has developed pharmacological strategies for the treatment of neurodegenerative diseases and neuromuscular disorders with small molecules and proteins.

#### Areas of research interest

Identify and manage external collaborations from research to early clinical development in neuromuscular disorders.

#### Contact

Pierre-Etienne CHABRIER  
Address: Ipsen Innovation, ZI de Courtaboeuf,  
5 avenue du Canada, 91940 Les Ulis, France  
Tel.1: +33 1 60 92 20 56  
Mail: pierre-et.chabrier@ipsen.com



### Sylvia JULIEN

Director Scientific Affairs Europe, IPSEN

#### Training and academic background

##### 2006-2007

POST-DOCTORAL SCIENTIST,  
Max-Planck-Institute of Biochemistry,  
Martinsried, Germany.

##### 2000-2006

DOCTORAL SCIENTIST & MASTER STUDENT,  
Institut Curie, Orsay, France.

##### 1997-2001

Ecole Normale Supérieure de Cachan,  
Biochemical and Biological Engineering  
Department.

#### Industry background

##### 2015-Present

Senior Project Leader External Partnerships,  
Director Scientific Affairs Europe/ Ipsen.

##### 2010-2009

Post-doctoral fellow – CReMEC Consortium / IPSEN.

#### Areas of research interest

Identify, implementing and monitor key external partnerships with biotech, academic and health care institutes which aims to complement & sustain Ipsen R&D innovation. Ipsen develops high standards in terms of partnerships based on mutual scientific interest and transparency to build a long-term win-win collaboration.

#### Contact

Sylvia JULIEN  
Address: Ipsen Innovation, ZI de Courtaboeuf,  
5 avenue du Canada, 91940 Les Ulis, France  
Tel.1: +33 1 60 92 20 00  
Tel. 2: +33 6 30 42 76 18  
Mail: sylvia.julien@ipsen.com



### Johannes KRUPP

Director – Toxin in vitro / Ipsen

#### Training and academic background

##### 2013

Ph.D. In Lifesciences with Specialization in  
Neurophysiology / Université Louis Pasteur  
Strasbourg, France.

##### 1989

Dipl.Biol. In Biology with Specialization in  
Neurophysiology/Johannes-Gutenberg-Universit  
ät Mainz, Germany.

#### Industry background

##### 2012-Present

Director Toxin in vitro / Ipsen

##### 2007 - 2012

Associate Director – Section head / AstraZeneca  
R&D Södertälje, Sweden

##### 2001 - 2004

Associate Principal Scientist – Project Leader  
AstraZeneca R&D Södertälje, Sweden

##### 1998 – 2001

Senior Postdoctoral Fellows / Vollum Institute,  
Oregon Health & Sciences University; Portland,  
OR; USA

##### 1993 – 1998

Postdoctoral Fellow 1994-1998 : Vollum  
Institute, Oregon Health & Sciences University;  
Portland, OR, USA  
Postdoctoral Fellow 1993-1994: Laboratoire  
Physiologie Générale, Université Louis Pasteur;  
Strasbourg, France

#### Areas of research interest

Neurology & toxins

#### Contact

Johannes KRUPP  
Address: Ipsen Innovation, ZI de Courtaboeuf,  
5 avenue du Canada, 91940 Les Ulis, France  
Tel.1: +33 1 60 92 20 35)  
Mail: johannes.krupp@ipsen.com



Company name: **Lilly**

Company size: **41 897 employees**

Number of countries: **125 countries**

Annual sales 2014: **20 Billions \$**

R&D Staff: **9 038 employees**

R&D investment: **4,8 Billions \$**

Net income: **2,4 Billions \$**

Headquarters: **Indianapolis (Indiana, U.S.A.)**

## COMPANY DESCRIPTION

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world.

For more than a century, we have stayed true to a core set of values excellence, integrity, and respect for people that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We have also been committed to investing in our employees through competitive salaries, training and development, health, and the opportunity to do well. The pharmaceutical industry is a complex, rapidly changing environment, and we are looking for highly capable leaders to help us continue making life better for people around the world.

## HISTORY OF COMMITMENT

For 140 years, Lilly has used its innovation-based strategy to discover, develop and deliver cutting-edge medicines that help improve the lives of people living with devastating diseases. Our approach to research and development Timely Valued Medicines to Patients underscores the importance of creating value for our stakeholders by accelerating the flow of medicines that lead to improved patient outcomes. Whether it's a compound we are developing on our own or through a partnership, our priority is getting treatments to patients in a timely manner.

Internal R&D: We recognize the importance of investing in one of our most valuable assets approximately 6,000 world-class scientists who are working tirelessly to discover and develop potential medicines faster than ever before. We always strive to complement this work with the best innovations outside the company.

Collaborations: Lilly is proud to be a leader in public-private partnerships and we are committed to bringing great minds together to help solve tough biomedical challenges, accelerating breakthroughs for patients who need them, and increasing the efficiency and cost-effectiveness of bringing new medicines to patients. Collaboration can bring together a wealth of knowledge and build upon existing science. In the end, this new model of investment helps streamline the discovery and development of new medicines in a way that can get treatments to people faster.

## PRODUCT PORTFOLIO IN THE AREA

### Our Current Products

- Amyvid™ (Florbetapir F 18 Injection) – Not commercialized in France
- Strattera® (atomoxetine) – Not commercialized in France
- ZypAdhera®(olanzapine long-acting)

### From Our History

- Cymbalta® (duloxetine)
- Zyprexa® / Zyprexa Velotab® (olanzapine) / Zyprexa® IntraMuscular
- Prozac® (fluoxetine)

### Pipeline in Neurosciences (June 2016)

- **Phase I :**  
Aβ monoclonal antibody Fab-PEG (Alzheimer disease), BACE inhibitor (Alzheimer disease), Anti-N3pG-AB monoclonal antibody (Alzheimer disease), Tau monoclonal antibody (Alzheimer disease), Dopamine D1 potentiator (Dementia), Pomaglumetad methionil (schizophrenia)
- **Phase II:**  
Edivoxetine (multiple CNS disorders), Florbazine (Parkinson's disease imaging agent)
- **Phase III:**  
Solanezumab (β amyloid antibody, Alzheimer disease ; pre-clinical Alzheimer disease), BACE inhibitor (Alzheimer disease),



Flortaucipir F 18 (Tau PET agent),  
Galcanezumab (CGRP monoclonal antibody;  
cluster headache, migraine prevention),  
Tanezumab (multiple pain indications).

## R&D Focus Portfolio and Prospective in this area

### Neurodegenerative diseases

- Novel therapeutic approaches for disease modification in neurodegenerative diseases, especially Alzheimer's disease and Parkinson's disease
- Novel treatments that address the symptoms of neurodegenerative diseases including psychosis, cognitive impairment, agitation, mood and sleep

### Pain and Migraine

- Novel approaches to treat chronic neuropathic, inflammatory and visceral pain
- Migraine prophylaxis

### Neuropsychiatric Symptoms of Disease

- Late stage opportunities to mood disorders with novel mechanisms
- Psychosis and agitation associated with indications such as Alzheimer's disease and Parkinson's disease

## Places of Worldwide Investigations

- Clinical research conducted in more than 55 countries
- Research and development facilities located in 6 countries
- Manufacturing plants located in 13 countries



### Walter DEBERDT

*Senior Medical Fellow for neuroscience in the Medical Department of Lilly Europe*

#### Training and academic background

Walter obtained honors medical degrees from the Catholic University of Leuven, Belgium. Post-graduate degree in Pharmaceutical Medicine. He trained in psychiatry at the University Hospitals in Leuven. His training in neurology included neuropathologic dementia research at the INSERM laboratories in Lille, France.

#### Industry background

In his position, Walter is the Neuroscience Medical Lead for France, Belgium, and The Netherlands and supports the clinical development of the Alzheimer portfolio. Since he started working for pharmaceutical companies about 30 years ago, he has acquired a large expertise in clinical drug development, data analysis, medical information, and health outcome research.

In 2005 he started working for the European Lilly organization where he supported the launch of olanzapine depot formulation and duloxetine, and the registration of atomoxetine for ADHD in adults.

Prior to that, Dr Deberdt worked in the US where he organized drug development in Borderline Personality Disorder and, later on, supported the clinical and health outcome research on Lilly's neuroscience products to public and private health organizations.

His publications include the areas of stroke, dementia, borderline personality disorder, schizophrenia, depression, and ADHD.

#### Areas of research interest

Neurosciences and psychiatry.

#### Contact

Walter DEBERDT  
Eli Lilly Benelux N.V. Markiesstraat 1/4B  
B - 1000 Brussel Belgium  
Tel.1: +32 2 5488615  
Mobile: +32 499 997 666  
Mail: [deberdt\\_walter@lilly.com](mailto:deberdt_walter@lilly.com)



### Rodrigo ESCOBAR

*Asia Lead Physician & Medical Fellow - Biomedicines Core Therapeutics and Pain*

#### Training and academic background

Residency in Psychiatry in Hospital Clinic i Provincial in Barcelona, Spain

#### Industry background

Rodrigo Escobar, MD, is currently Asia Lead Physician & Medical Fellow in the Biomedicines Core Therapeutics and Pain at Eli Lilly and Company. Dr. Escobar has more than 15 years of experience in pharmaceutical industry with extensive international experience in EU, Japan and US. He is the former Global Senior Medical Director for Psychiatry and Pain in Indianapolis (US); previously he led the Neuroscience Medical team in Lilly Japan, and also worked as European Regional Physician. Rodrigo is psychiatrist by training with deep experience in R&D and his ultimate goal is impacting on the benefit of the patients and families from the pharmaceutical industry.

Before joining Eli Lilly and company he worked as clinical psychiatrist in Spain and as Assistant Professor in Psychiatry and Chief of In-patient psychiatry unit of University Hospital (San Vicente de Paul Hospital) in Colombia. He was Secretary and Treasurer of the Colombian Biological Psychiatry Association and Board Member of the Colombian Psychiatry Association.

He is author/coauthor of several publications in neurosciences and neuropsychopharmacology including both pediatric and adult drug development topics.

#### Areas of research interest

Neurosciences and neuropsychopharmacology.

#### Contact

Rodrigo ESCOBAR  
Lilly España Avenida de la Industria, 30  
28108 Alcobendas. Madrid  
Tel.1: +34 91 623 1522  
Mobile: +34 606 458 850  
Mail: [escobar\\_rodrigo@lilly.com](mailto:escobar_rodrigo@lilly.com)



### Karim HAMIDI,

*Medical Advisor, Medical Manager Psychiatry, Urology, Osteoporosis France & Benelux*

#### Training and academic background

Karim obtained honors medical degrees from the Medical Faculty of Medicine of Algiers, Algeria. Post-graduate degree in Infectious Diseases in Paris. He works several years in Bichat Claude Bernard Hospital in Emergency Care and Infectious Diseases departments as well as co-investigator and for the ANRS (AIDS National Research Agency) in France.

#### Industry background

In his position, Karim is the new Pain/Migraine Medical Lead for France, Belgium and The Netherlands and supports the clinical development of the Pain/Migraine portfolio. Since he started working for pharmaceutical companies about 19 years ago, he has acquired a large expertise in medical affairs, clinical drug development, data analysis, medical training and medical information.

He worked several years in Medical Affairs in the field of AIDS in different pharmaceutical companies.

In 2000 he started working at Lilly for the registration and launch of a new drug in Urology, and between 2006 and 2012, he works for the launch of a new drug in lung cancer.

Since 2012, he works in the field of Urology and more recently in Osteoporosis.

#### Areas of research interest

Neurosciences.  
Infectious Diseases.

#### Contact

Karim HAMIDI  
Lilly France 24 Boulevard Vital-Bouhot  
92200 Neuilly Sur Seine  
Tel.1: +33 1 55 49 33 58  
Mobile: +33 6 89 95 11 34  
Mail: [hamidi\\_karim@lilly.com](mailto:hamidi_karim@lilly.com)



### Jennifer LAIRD

*Senior Director, Search & Evaluation*

#### Training and academic background

Doctorates from Bristol University, UK, and University of Alicante, Spain.

#### Industry background

Before joining Lilly in 2012, Dr. Laird spent 10 years at AstraZeneca as Executive Director heading Translational Science, Project Director leading preclinical and early development projects, and Associate Director leading a Pharmacology group.

Prior to that, she held positions as an academic PI and at Merck's Neuroscience Research Centre in the UK.

Dr. Laird has a background in neuroscience with more than 80 publications, including papers in Nature, PNAS and the Lancet, is a member of the Editorial Boards for Neuropharmacology and the European Journal of Pain and holds an honorary appointment as Professor of Pharmacology at McGill University, Canada.

#### Areas of research interest

The Search & Evaluation team complements Lilly's internal R&D efforts with external innovation by evaluating and in-licensing assets and technologies, as well as working in collaboration with multiple external partners to advance molecules through discovery and early development.

#### Contact

Jennifer LAIRD  
Eli Lilly and Company Erl Wood Manor,  
Sunninghill Road, Surrey, GU20 6PH, UK  
Tel.1: +44 1276 483149  
Mail: [laird\\_jennifer@lilly.com](mailto:laird_jennifer@lilly.com)



### Christer NORDSTEDT

*Vice President, Neuroscience Discovery Research and Clinical Investigation*

#### Training and academic background

Christer Nordstedt obtained both his M.D. and Ph.D. from the Karolinska Institute in Stockholm, Sweden.

He was a post-doc in Nobel Laureate Paul Greengard's laboratory at the Rockefeller University in New York City.

#### Industry background

Christer Nordstedt, M.D., Ph.D., joined Eli Lilly and Company as Vice President of Neuroscience Discovery Research and Clinical Investigation in June 2011. In his current position, Dr. Nordstedt oversees Lilly's global neuroscience drug discovery and early clinical development.

Prior to joining Eli Lilly and Company he was Global Vice President for CNS Discovery at Hoffmann-LaRoche where he was recruited in 2007.

Before that he was Vice President for Neurology and Pain Research at AstraZeneca he joined in 2000. Prior to that, he started working in 1997 at Hoffmann-LaRoche (Roche) in Basel Switzerland as a Lab Head on Alzheimer's disease.

After his post-doc, he returned to the Karolinska Institute in 1992, where he started his own laboratory focusing on various molecular aspects of Alzheimer's disease.

#### Areas of research interest

Neuroscience drug discovery and early clinical development.

#### Contact

Christer NORDSTEDT  
Lilly Research Laboratories Lilly Corporeate  
Center Indianapolis IN 46285 USA  
Tel.1: +1 317 276 0011  
Fax: +1 317 276 7600  
Mail: [nordstedt\\_christer@lilly.com](mailto:nordstedt_christer@lilly.com)



**Elena PERRIN**  
Senior Medical Director France & Benelux

#### Training and academic background

MD and Psychiatrist (University of Paris V René Descartes, France)  
Master of Pharmacokinetics and Statistics (University of Paris Pitié-Salpêtrière, France)  
International executive program (INSEAD, France)

#### Industry background

Elena Perrin, MD, is a Psychiatrist and the Senior Medical Director for France and Benelux, in charge of all medical, regulatory, pharmacovigilance and research implementation.

Dr Elena Perrin has more than 20 years of experience in clinical research, medical affairs, and leading teams in pharmaceutical industry, in France and abroad.

She has worked for Lilly France for many years and has been in charge of several missions during her career: medical information manager, Clinical Research Physician in the neuroscience field, Neuroscience Medical Director for France. In 2006, she has been responsible for the neuroscience portfolio in Europe and leading the neuroscience group for Europe, Australia and Canada.

Since 2011, Dr. Perrin is the Senior Medical Director.

She authored several publications and books chapters, active member of the World Physicians Association.

#### Areas of research interest

Fields: neurosciences, auto-immune disease, diabetes, oncology.

#### Contact

Elena PERRIN  
Lilly France 24 boulevard Vital Bouhot - CS 50004  
92521 Neuilly-sur-Seine Cedex  
Tel.1: +33 1 55 49 33 66  
Mobile: +33 6 80 34 42 31  
Fax: +33 6 80 34 42 31  
Mail: perrin\_elena@lilly.com



**Company name: Merck**

**Company size: 50 000 employees**

**Number of countries: 66 countries**

**Annual sales 2014: 11,3 Billions \$**

**R&D Staff: 5 000 employees**

**R&D investment: 1,7 Billions \$ (2015)**

**Net income: na**

**Headquarters: Darmstadt, Germany**

## COMPANY DESCRIPTION

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

## HISTORY OF COMMITMENT

Merck has a long-term commitment to developing innovative treatments to help manage neurodegenerative diseases such as multiple sclerosis (MS).

We are also deeply committed to changing the cancer landscape. Our immuno-oncology (iONC™) research and early development platform, integrating research, early development and biomarker strategies, focuses on discovering and developing potential new therapies that are intended to harness the immune system and activate or augment the body's natural anti-tumor response.

## PRODUCT PORTFOLIO IN THE AREA

Our neurodegenerative disease franchise is led by the flagship product, Rebif® (interferon beta-1a) for relapsing forms of multiple sclerosis (MS). We design and develop intelligent devices that provide ongoing care for patients beyond their treatment, our injection device and disease monitoring software make it possible for patients with multiple sclerosis to self-inject their medicine and monitor its administration.

## R&D FOCUS PORTFOLIO AND PROSPECTIVE IN THIS AREA

The current immuno-oncology portfolio comprises therapeutic candidates in early clinical development and a pipeline of preclinical molecules including avelumab, a fully human anti-PD-L1 IgG1 monoclonal antibody thought to enable the activation of T-cells and the adaptive immune system.

Our development pipeline in immunology include Sprifermin (Fibroblast Growth Factor 18), a recombinant protein that increases cartilage cell proliferation and production of extra-cellular matrix components – leading to repair and reconstruction of cartilaginous tissue. Sprifermin is being studied in both osteoarthritis (OA) and cartilage injury (CI). Another innovative drug candidate is the soluble fusion protein atacicept, which is being studied in the autoimmune disease systemic lupus erythematosus (SLE).

We are currently pursuing opportunities for indication expansion into neurological diseases with high unmet medical need that have commonalities with MS in disease pathophysiology and clinical symptomatology. We have launched this effort with a re-purposed molecule for external development by EspeRare (Rare Disease Foundation) in Duchenne's Muscular Dystrophy. In addition, we are actively pursuing opportunities in other neuro-inflammatory, demyelinating or neurodegenerative diseases. Finally, Cladribine Tablets, a lymphocyte targeting agent is under submission for relapsing-remitting MS.



**Pierre-Henry LONGERAY**  
President of Biopharma activities of Merck in France

#### Training and academic background

Doctor in Pharmacy

#### Industry background

In the pharmaceutical industry since 1986, I joined the Market Research team at Lipha (Lipha became part of the Merck Group in 1991). During my career with Merck, I have worked in several positions :

#### 1990

General Manager in Belgium, then I held different positions as Manager in Marketing and Sales in France and in International Marketing in Lyon.

#### 2000

President of Theramex in Monaco, the division of Merck specialising in Women's Health.

#### 2002

Responsible Pharmacist for Merck Sante.

#### 2007

President of the Biopharma activities of Merck in France.

#### I am also:

- Vice-President of the ARIIS Executive Committee (Alliance pour la Recherche et l'Innovation des Industries de Santé)
- Member of the LEEM board (Les Entreprises du Médicament - The French Pharmaceutical Association),
- Vice-President of the LEEM Biotech Committee. Member of CODEEM (Leem Deontovigilance Committee)

#### Areas of research interest

Immuno Oncology, Oncology, Fertility, Immuno & Neurology.

#### Contact

Pierre-Henry LONGERAY  
Merck Santé s.a.s.  
37 rue Saint-Romain, 69008 Lyon, France  
Tel.1: +33 4 72 78 29 72  
Mail: pierre.henry.longeray@merckgroup.com



**Anne Sophie JEAN DELEGLISE**  
Medical Manager Neurology

#### Training and academic background

Medical Doctor from Lyon University (France). Expert in Multiple Sclerosis (MS), working on environment and MS therapies, with a focus on real life data generation.

#### Industry background

Several positions in pharmaceutical company since 18 years (MSL, sales force trainer, Market Access lead) covering many therapeutic areas (fertility, endocrinology, dermatology, immunology, neurology). Currently working in the Medical Affairs Department.

#### Areas of research interest

Neurology and Immunology: Multiple Sclerosis, Systemic lupus erythematosus, osteoarthritis.

#### Contact

Anne Sophie JEAN DELEGLISE  
Merck Santé s.a.s.  
37 rue Saint-Romain, 69008 Lyon, France  
Tel.1: +33 4 72 78 24 06  
Mobile: +33 6 30 48 71 05  
Mail: anne-sophie.jeandeglise@merckgroup.com



**Benoît van HILLE**  
Medical Operation Manager

#### Training and academic background

PhD in Molecular Biology (reproduction endocrinology).  
Engineering Degree.

#### Industry background

After years in academic research, in the pharmaceutical company since 22 years (scientist group leader, contract manager, product and marketing manager) covering several therapeutic areas (oncology, neurology, osteoporosis).

Currently working in the Medical Affairs Department as medical operations manager. In charge of insuring optimal quality and methodologies in medical excellence, and develop real world evidence by valorizing pharmaco-epidemiological data.

Skills and experience : identify disease-related genetic targets for drug screening, clinical trials, patient support services.

#### Areas of research interest

Oncology & Neurology.

#### Contact

Benoît van HILLE  
Merck Santé s.a.s.  
37 rue Saint-Romain, 69008 Lyon, France  
Tel.1: +33 4 72 78 28 35  
Mobile: +33 7 60 64 24 46  
Mail: benoit.van.hille@merckgroup.com



**Raphaël EYMARD**  
Local Business Development

#### Training and academic background

Healthcare Business Development & Licensing Training (in & out).  
Master in Learning & Development.

#### Industry background

In the pharmaceutical industry since 10 years,  
Local representative of Business Development organization of the Healthcare division .  
Project Manager of technologies & drugs launched.  
Change management specialized in Innovation & digital solutions.

#### Areas of research interest

Immuno Oncology, Oncology, Fertility, Immuno & Neurology.

#### Contact

Raphaël EYMARD  
Merck Santé s.a.s.  
37 rue Saint-Romain, 69008 Lyon, France  
Tel.1: +33 4 72 78 25 91  
Mobile: +33 7 62 97 28 40  
Mail: raphael.eymard@merckgroup.com



**Company name: MSD**

**Company size: 68 000 employees**

**Number of countries: more than 140 countries**

**Annual sales 2015: \$39,5 billion**

**R&D investment: \$6.6 billion**

**Headquarters: Kenilworth, New Jersey, USA**

### COMPANY DESCRIPTION

MSD is a global leader in delivering innovative health solutions through its medicines, vaccines, biologic therapies, consumer and animal health products. MSD also demonstrate its commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD is known as Merck in the United States and Canada.

MSD product offering categories include heart and respiratory health, infectious diseases, diabetes, cancer, inflammatory diseases and women's health.

MSD focus research on conditions that affect millions of people around the world - diseases like Alzheimer's, diabetes and cancer.

### HISTORY OF COMMITMENT

Since 1891, our researchers have helped to find new ways to treat and prevent illness — from the discovery of vitamin B1, to the first measles vaccine, to cold remedies and antacids, to the first statins to treat high cholesterol. Today, as a research-intensive biopharmaceutical company, we're focused on making important scientific advancements within hepatitis C, HIV, diabetes and immuno-oncology, Alzheimer disease. While we are proud of our past, we are enthusiastic about the future. We aim to create a healthier, brighter future for people around the world.

### PRODUCT PORTFOLIO IN THE AREA

Today, Merck has more than 50 prescription products in key therapeutic areas, such as cardiovascular disease, respiratory disease, oncology, neuroscience, infectious disease, immunology and women's health.

For more information

<http://www.merck.com/product/home.html>

### R&D FOCUS PORTFOLIO AND PROSPECTIVE IN THIS AREA

#### Several research programs :

In neurosciences

Alzheimer's Disease : an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE) that is being evaluated in clinical trials for the treatment of Alzheimer's disease (Phase III).

#### Overview on MERCK R&D pipeline :

##### 15 PHASE II PROGRAMS

- Advanced solid tumors
- Asthma
- Cough
- Diabetes
- Heart Failure
- Hepatitis C
- Hodgkin Lymphoma
- Liver Cancer
- Nasopharyngeal Cancer
- Ovarian Cancer
- Pneumoconjugate Vaccine
- Primary Mediastinal Large B-Cell Lymphoma
- Prostate Cancer

##### 19 PHASE III PROGRAMS

- Alzheimer's disease
- Atherosclerosis
- Bacterial Infection
- Bacterial Pneumonia
- Bladder Cancer
- Breast Cancer
- CMV Prophylaxis
- Colorectal Cancer
- Diabetes
- Ebola Vaccines
- Esophageal Cancer
- Gastric Cancer
- Head and Neck Cancer
- Herpes Zoster Vaccine
- HIV
- Multiple Myeloma

##### 6 UNDER REVIEW

- Allergy
- C Difficile Infection
- Diabetes
- Head and Neck Cancer
- Lung Cancer

For more information on the entire MSD research program.

<http://www.merck.com/research/pipeline/home.html>

MSD's research and clinical development program is global and involves countries and scientific leaders from:

North America, Europe, South America, Africa, Australia, and Asia.



#### Nawel YAKOUBI

*Manager of Scientific Partnerships at MSD France*

#### Previous experiences :

Medical Advisor in Rheumatology, Anesthesia, at MSD France.

Project Manager at HAS (HTA).

Physician at Biosys, biotech producing monoclonal antibodies.

#### Contact

Nawel YAKOUBI  
MSD France  
34 avenue Léonard de Vinci | 92418 COURBEVOIE  
Cédex I FRANCE



**Company name: Novartis Bioventures Ltd**

**Company size: 15 employees**

**Number of countries: offices in Basel, Boston, Bermuda**

### COMPANY DESCRIPTION

The Novartis Venture Fund (NVF) manages over \$700 million in committed capital. NVF invests in companies that have the potential to change a core therapeutic field or explore new business areas that will be critical to patient care. NVF's primary interest is in the development of novel therapeutics and platforms as well as medical devices, diagnostics, and delivery systems.

The Funds invest for financial objectives at all stages, but prefers to invest in the early-stages of company development. With investment professionals located in Basel, Switzerland and Cambridge, MA the team has extensive experience in pharmaceutical R&D and venture capital.



#### Florent GROS

*Managing Director – Novartis Venture Funds*

Dr. Florent Gros is a Managing Director of the Novartis Venture Funds in Basel, Switzerland. For nearly 18 years he held various positions and projects in the intellectual property and venture areas at Nestlé, Pasteur Mérieux Connaught and Novartis. Florent started at Nestlé in Switzerland, managing intellectual property arising from Nestlé's research centers around the world. Florent joined Pasteur Mérieux Connaught in France (now Sanofi-Pasteur) as the European head of the IP

Department. Later, Florent joined the Novartis Corporate Intellectual Property Department in Switzerland and was a member of Novartis Pharma and Research Executive Licensing Committees.

Florent also lived in Cambridge, USA and set up there the patent department of Novartis. Since 2006 Florent joined the Novartis Venture Funds and is leading private equity investments into European-based healthcare startups. Florent currently serves on the boards of Myopowers (CH), Opsona (IE), Atlas Genetics (UK), Anokion (CH), Kanyos (US), Adicet (US) and Inflazome (IE).

His prior investments resulted to successful acquisition and IPO listings: Okairos, Neovacs, Tigenix, Evolva, Merus and Gensight.

Florent is a Kaufmann Fellow (class 12), holds a Biotechnology Engineering Master Degree in France, and made his diploma thesis on vaccines at Glaxo-Vaccine in Belgium. He also holds European and French patent lawyer degrees, and another Master Degree in Private Law.



**Company name: PFIZER**

**Company size: 97 000 employees**

**Number of countries: Present in 175 countries**

**Annual sales 2015: \$49 billion**

**R&D investment: \$7.7 billion**

## COMPANY DESCRIPTION

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at [www.pfizer.com](http://www.pfizer.com). In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer\_News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

## HISTORY OF COMMITMENT TO NEUROSCIENCES

In the US today, seven of the ten leading causes of disability are caused by central nervous system (CNS) disorders, and the combined estimated US and EU economic burden of such disorders is over \$1.5 trillion and growing. Pfizer is a global leader in this space and continues to invest heavily with products in each of the major classes.

In Neuroscience, we are investigating new ways to attack Alzheimer's Disease, Parkinson's Disease, and Schizophrenia, as well as a wide range of disorders that manifest symptoms which are common to several diagnoses, such as impaired cognition

## PRODUCT PORTFOLIO IN THIS AREA

Please follow link to Pfizer pipeline: <http://www.pfizer.com>

## PROSPECTIVE IN THE AREA : THEMATIC PRIORITIES

Pfizer WRD is interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:

### Neuroscience – Primary areas of interest:

- Neurodegenerative Diseases
- Alzheimer's Disease (AD) including strategic partnerships on Pfizer assets
- Parkinson's Disease (PD)
- Trans diagnostic domains relevant to psychiatric disorders such as Cognition, Anxiety, and Motivation/Apathy

### Other areas of focus:

- Huntington's Disease (HD): siRNA and knock down approaches, symptomatic and diseasemodifying treatments
- Vascular Dementia (Cerebellar Amyloid Angiopathy)
- Multiple Sclerosis (MS) – Remyelination targeting Chronic Progressive disease only
- Cerebrovascular disease- sensory disorders involving abnormal sensations of clinical relevance, e.g., visual, auditory, vestibular, or somatosensory systems
- Agents modulating (or biomarkers of) chronic neuroinflammation with evidence of impact on AD or PD neurodegeneration
- Imaging agents (e.g., tau, synuclein, neurotransmitters, neuroinflammatory markers and gliosis)
- Conformational antibodies that have cross reactivity to all "amyloids" (e.g., tau, Aβ, huntingtin, δ-synuclein)

Along with our Rare Disease Research Unit, we have an interest in rare CNS diseases and in novel technologies to address them (such as gene therapy).

### Pfizer WRD is not actively seeking partnering opportunities in: Neuroscience

- Protein "anti-aggregators"

- Aβ immunotherapies or vaccines
- Anti-oxidants directed to neurology indications
- COMT Inhibitors; MAO Inhibitors
- Undifferentiated anti-psychotic or antidepressant drugs
- GlyT1 inhibitors, H3 Inhibitors, PDE Inhibitors (2, 4, 9, 10), mGluR5 inhibitors, or a4b2 nicotinic agonists
- Stand-alone mania treatments
- Stroke treatments without proof of concept in humans
- MS approaches that primarily target patients with relapsing remitting disease
- Large molecule therapeutics with CNS targets absent data for brain penetration
- "Black box" mechanisms



### Uwe SCHOENBECK

*Chief Scientific Officer  
External R&D Innovation (ERDI)  
Senior Vice President, Pfizer Worldwide R&D*

Chief Scientific Officer Uwe Schoenbeck leads Pfizer's Worldwide Research and Development (WRD) External R&D Innovation (ERDI) team which seeks to identify and establish partnerships with outstanding Pharma and Biotech companies and key academic centers to gain first access to cutting edge science and innovative disease targets, drug candidates as well as platform technologies. The function involves global scouting for and the integration of exploratory to clinical Proof of Concept drug candidates as well as technologies addressing high unmet medical needs and covers both small and large molecule approaches together with gene & cell therapies. His team works closely with colleagues across Pfizer, including all of WRD's key therapeutic research units, as well as business development, business units, and Pfizer country organizations to harness these opportunities for the company. Uwe is also a member of the WRD Leadership Team and sits on Pfizer's Senior Leadership Council.

Prior to joining Pfizer in 2009, Uwe was Vice President, External R&D Innovation for Wyeth Pharmaceuticals and was a member of the Wyeth's R&D Executive Committee where he was responsible for developing and implementing

Wyeth's External R&D strategy and operations. Preceding his time at Wyeth Uwe served as the Vice President, Cardiovascular Research for Boehringer Ingelheim in Ridgefield, CT, and was responsible for the global cardiovascular research strategy and drug discovery program from target identification to Pre-Development including life cycle management for marketed and advanced pipeline products. Prior to joining Boehringer in 2003, he held the position of Assistant Professor of Medicine, Brigham & Women's Hospital, Harvard Medical School.

Uwe received his degree from the University of Kiel, Germany, and completed postdoctoral training in the Division of Cardiovascular Medicine, Brigham & Women's Hospital, Harvard Medical School, before joining as a faculty member. Uwe has served as a reviewer for multiple peer-reviewed journals (incl. Circulation, Circulation Research, Journal of Clinical Investigation, Journal of Experimental Medicine, Journal of Immunology, Journal of the American College of Cardiology (JACC), Nature Medicine, and the Proceedings of National Academy of Sciences U.S.A.) and has published more than 100 peer-reviewed articles, review articles/book chapters and abstracts with particular contributions in areas such as molecular & cell biology, cardiovascular research, immunology and metabolism.



### Sree KANT

*Chief Scientific Officer  
Head of Strategy - External R&D Innovation,  
Pfizer*

Sree Kant is the Head of Strategy for Pfizer's External R&D Innovation Group, leading partnership strategy across different therapeutic areas/technologies and geographies. He is focused on innovative partnering that can drive value for both Pfizer and partner, especially in new emerging science and technology areas. Before joining Pfizer, he was a Principal at the Boston Consulting Group advising large pharma and biotech on R&D strategy as well as large M&A. Sree has also worked with two healthcare startups and a generic pharmaceutical company in India and the UK. He has an MBA from the Indian Institute of Management, and an MPH from the Harvard School of Public Health.



### Nathalie TER WENGEL

*ERDI Global Scouting Lead, EU*

Nathalie ter Wengel, a medical doctor, is the European Lead Global Scouting External R&D and Innovation at Pfizer, where she is responsible for establishing new collaborations and exploring licensing and other corporate development opportunities across all therapeutic areas. She has an international background and a broad knowledge in the medical field, having worked in the hospital with extensive experience in internal medicine.

Nathalie started her commercial career as European Medical Manager at Pfizer, where she successfully led ambitious international projects, combining a business perspective with her medical knowledge. It was this experience, coupled with her father's illness, that convinced her of the urgent need for change in the pharmaceutical industry.

Consequently, she started up a company called myTomorrows focused on compassionate use, and served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very successful NASDAQ IPO and in partnering filgotinib.



### Laszlo KISS

*Global Neuroscience Lead*

Dr. Laszlo Kiss is the Global Neuroscience Lead, ERDI. Laszlo has over 18 years of drug discovery, development and management experience. He

has a successful track record in leading CNS, CV and Rare Disease drug discovery programs from early exploratory research through clinical development. Prior to joining Pfizer, Laszlo held various roles of increasing responsibility at Bristol-Myers Squibb, Essen Biosciences and Merck & Co.

Laszlo earned his Ph.D. in Physiology and Neurobiology from the University of Connecticut and completed his post-doctoral training in Neuroscience at the University of California at San Diego.

He is the author of more than 50 scientific publications in peer reviewed journals, book chapters, abstracts and patents. Laszlo has served on grant review panels at the National Institutes of Health, National Institute of Neurological Disorders and Stroke.



### Bernard PRIGENT

*Regional Medical Affairs Lead, Europe*

Trained as a family physician, completing his MD in Public Health & Tropical Medicine in Paris. Joined the pharmaceutical industry in 1984 and acquired a broad experience in Pharmaceutical Medicine and Drug Development working successively for the International Medical Operations of Sanofi Pharma International (Paris), Glaxo Holdings PLC (London) and Ciba-Geigy (Basel).

During his time in the United Kingdom he completed his MBA at Henley Management College.

Joined Pfizer Canada in 1995 and worked in various leadership roles within the Medical and R&D organisation including Vice-President, Medical Affairs EUCAN Brand Teams, Vice-President and Medical Director Pfizer Canada and Vice-President, Pfizer Global Research and Development.


**Robert MATHER**

*Head of Neuro-Opportunities Group  
Neuroscience & Pain Research Unit*

Robert "Joe" Mather currently leads the Pfizer Neuro-Opportunities Group in the Neuroscience & Pain Research Unit (NPRU) in Cambridge, Massachusetts, USA where he and his team evaluate external opportunities, partnerships, and collaborations that align with the NPRU research strategy.

Previously, Joe was with AstraZeneca as a Project Director in the Neuroscience iMED in Cambridge, Massachusetts (USA) where he worked to build a fully externalized research team. In addition to his iMED responsibilities, Joe led a group of dedicated post-doctoral fellows alongside Professor Stephen Moss as the co-director of the AstraZeneca-Tufts Lab for Basic and Translational Neuroscience at Tufts Medical School in Boston.

Joe has over twenty years of research and development experience and was notably part of the Chantix discovery team. Joe's scientific career has focused on understanding how neuronal excitability impacts neurological disorders. Joe has led late stage discovery and early clinical development programs and successfully established highly collaborative partnerships with organizations including: the Michael J. Fox Foundation, Rett Syndrome Research Trust, and NIH/NIDA.


**Gautam GUPTA**

*VP – Strategy, Portfolio, Competitive Intelligence  
and Operations - Worldwide Research and  
Development, Pfizer Inc*

Gautam is accountable for shaping Pfizer's R&D strategy, monitoring and enhancing the value of its pipeline and driving continuous improvement initiatives. At the Divisional and Corporate level, he ensures key R&D decisions are linked to overall strategic priorities, competitive context and financial considerations. He's a member of the R&D Leadership Team and supports strategic dialogue with key stakeholders such as the Board, CEO, analysts, shareholders and the scientific community.

Prior to joining Pfizer, Gautam spent ten years at The Boston Consulting Group (BCG), a leading global strategy consulting firm. As a Senior Principal in the firm's Healthcare Practice, Gautam worked with a host of Biotech and Pharmaceutical companies on high priority issues such as portfolio & innovation strategy, R&D productivity, organizational redesign and post-merger integration. Gautam earned his M.B.A. from the Indian Institute of Management in Ahmedabad, India, with a focus on Strategy and Finance. He received his B.A. in Economics from St. Stephen's College at the University of Delhi, India.


**Michael METCALFE**

*GIP Sr Med Director NS/Pain EU*

Michael Metcalfe qualified with MBChB from Edinburgh University Medical School in 1996. He

trained in clinical Paediatric Medicine in the UK and New Zealand before joining the pharmaceutical industry in 2002.

Michael has been active in the area of tobacco dependence since 2006, and has authored papers on varenicline use in smokeless tobacco use, and multi-centre observational studies in smoking cessation. He has shaped the development of regional medical strategy including educational and independent research programmes.

He is currently Senior Medical Director with Pfizer's International Developed Markets Medical Affairs Department, responsible for Pain and CNS products. He holds the UK Diploma of Pharmaceutical Medicine and is a member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.


**Robert C. ALEXANDER**

*Vice President and Head, NPRU and RDRU  
Clinical Pharmacology and Statistics  
Clinical Head, Neuroscience & Pain Research*

Robert C Alexander, M.D., received his undergraduate and medical degrees from University of Chicago and completed his post-graduate work at McLean Hospital/Harvard Medical School, the National Institute of Mental Health and Columbia University. During his career, Dr. Alexander has held a number of academic positions and hospital appointments and is currently a Consultant in the Psychiatry Department at the Massachusetts General Hospital. Prior to Pfizer, he led early clinical groups at AstraZeneca and GlaxoSmithKline, and was a Senior Director in Clinical Neuroscience and Clinical Pharmacology at Merck Research Labs. Dr. Alexander has extensive experience in clinical trials, both early and late stage drug development, and medical governance and has published 59 peer-reviewed papers.



**Company name: ROCH**

**Company size: 91 700 employees**

**R&D staff: 18 449 employees**

**Annual sales 2015: 48.1 billion Swiss francs**

**R&D investment: 9.3 billion Swiss francs**

**Net income: 9.05 billion Swiss francs**

## COMPANY DESCRIPTION

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, and its focus is on creating truly innovative medicines and diagnostic tests in areas of unmet medical need.

Roche is also leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Roche's personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization (WHO) Model Lists of Essential Medicines, among them lifesaving antibiotics, antimalarials and chemotherapy.

In 2015, the Roche Group employed 91,700 people worldwide, invested 9.3 billion Swiss francs in R&D and posted sales of 48.1 billion Swiss francs.

For more information, please visit [roche.com](http://roche.com).

All trademarks used or mentioned in this release are protected by law.

## HISTORY OF COMMITMENT

Millions of people worldwide continue to suffer from debilitating conditions that have limited treatment options and poor prognosis. At Roche we invest in research and development to

transform science into medicines and diagnostic tests to address these patient needs.

We take a focused approach to increase our chance of success in highly complex diseases. We focus on a select group of diseases areas including oncology, hematology, neuroscience, immunology and inflammation, ophthalmology, infectious and rare diseases.

Therefore Personalized Health Care is key to improve patients' daily life, to find the right treatment for the right patient. To achieve this ultimate goal Diagnostics and Pharma are working together to find the right solutions.

## PRODUCT PORTFOLIO IN THE AREA

Roche has made pioneering discoveries in neurosciences e.g. benzodiazepines, levodopa, monoamine oxidase inhibitors.

The current commercial portfolio is constituted, in France, of:

- Lexomil® (bromazepam), for the treatment of anxiety
- Modopar® (levodopa and benzeraside combination) for the treatment of Parkinson disease
- Rivotril® (clonazepam) for the treatment of adult and child epilepsy
- Valium® (diazepam) for the treatment of anxiety and alcohol withdrawal
- Versed® (midazolam), a fast-onset hypnotic sedative for vigil sedation

In addition we have a number of investigational medicines in clinical development for neuropsychiatric disorders, including multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Down syndrome, autism spectrum disorders and pain (see : <http://www.roche.com/>).

## R&D FOCUS PORTFOLIO AND PROSPECTIVE IN THIS AREA

We strive to address unmet medical needs through excellence in science. Breakthrough innovation in science and technology increasingly allow us to understand precisely what is malfunctioning in the body and develop drugs to counter the problem. We focus on five major therapeutic areas but remain flexible and follow the science as new insights become available. In neurosciences, by using a

multidisciplinary approach and a wide range of technologies, we seek to unravel the fundamental mechanisms underlying the biology and the diseases of the nervous system, and to translate these discoveries into innovative therapies for neurological disorders, psychiatry and pain.

With one of the strongest pipelines in the industry, Roche Neuroscience is developing medicines for a range of serious neurological diseases, including multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, autism, depression, schizophrenia and pain.

In Neuroscience we are at a turning point in our understanding of the brain and the nervous system with the last ten years being crucial in unveiling biologic mechanisms behind the pathology of neurological disorders. This provides tremendous opportunities.

Roche Neuroscience addresses areas of high unmet medical need with no approved, effective or safe medicines. Via a mechanism-based drug discovery, we aim an early intervention and personalized treatment of serious brain disorders.

Biomarkers are also helping us develop more targeted treatments for disorders, such as Alzheimer's, which affects more than 20-25 million people worldwide.

### Roche Neuroscience focuses on four major disease areas:

Neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer's disease (AD), Multiple Sclerosis (MS), and amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD). Roche focuses on an early intervention and selection of patients eligible for a specific treatment based on biomarkers.

Pain, chronic pains, including neuropathic pains, novel pain targets through human genetics (e.g. gain of function pain syndromes), new pain targets (e.g. mechanical allodynia).

Psychiatric disorders, including schizophrenia and treatment-resistant depression. In schizophrenia we target negative symptoms and cognition improvement (while most of existing treatment target positive symptoms). Treatment-resistant depression include the ~35% of depressive patients that do not respond to standard of care.

Neurodevelopmental disorders, including autism spectrum disorders, Down syndrome and Fragile X. In these diseases of the development of the brain we are focusing on the treatment of core symptoms, like social interaction, communication deficits and restricted repetitive behaviors.

## PLACES OF WORLDWIDE INVESTIGATIONS

Our diverse approach to research and early development is carried out by four organizations: Genentech Research and early development -gRED (Genentech, in the United States, is a wholly owned member of the Roche Group and has been delivering on the promise of biotechnology for over 35 years), Roche Pharma Research and early development- pRED, Chugai Pharmaceutical Co., Ltd., Japan (a member of the Roche Group), and our Diagnostics Division. Roche's partnering functions maintain close links to external organizations and we currently have partnerships and alliances with more than 240 external companies and institutes.

gRED is located in South San Francisco (US), pRED is located in Basel (Switzerland), Schlieren (Switzerland), Penzberg (Germany) and Shanghai (China). Chugai has three core research laboratories in Japan: Fuji Gotemba (Gotemba City), Kamakura (Kamakura City) and Ukima (Kita-ku, Tokyo).

Roche Group has about 15 R&D sites and 20 production sites worldwide.

## LA RECHERCHE DANS LE GROUPE ROCHE : L'INSTITUT ROCHE UNE STRUCTURE UNIQUE

Afin de constituer et de maintenir la richesse de son pipeline de molécules biopharmaceutiques, Roche a construit une structure de R&D unique qui comprend 2 pôles de Recherche et Développement :

- Pharma Research & Early Development (pRED),
- Genentech Research & Early Development (gRED).

Ces pôles fonctionnent de manière indépendante au sein du Groupe, mais aussi en collaboration avec plus de 150 partenaires externes de renommée internationale. Ces alliances avec des

universités, des instituts de recherche et aussi des entreprises de biotechnologie permettent d'alimenter la diversité des approches de recherche, d'accéder aux dernières technologies ainsi qu'à de nombreuses molécules prometteuses.

L'Institut Roche joue, depuis quelques années, un rôle majeur en France dans la construction et le pilotage scientifique de nombreuses collaborations entre les acteurs français de la recherche et les pôles du Groupe Roche.

Depuis 2009, il a permis de mener 140 programmes scientifiques et représente un investissement de plus de 40 millions d'euros dans des partenariats « public-privé », qui ont donné lieu à 46 publications et 4 dépôts de brevet.

L'Institut Roche compte actuellement plus d'une trentaine de partenaires répartie sur l'ensemble du territoire français avec 55 programmes scientifiques en cours en 2015, notamment en oncologie, neurosciences, maladies infectieuses et maladies rares.



**Ludovic LERICHE**

*Scientific Alliances Manager - Neurosciences*

### Training and academic background

#### 2006

Post-doctoral fellow, Isotopic Imagery Biology and Pharmacology, CEA, Orsay

#### 2000 - 2005

PhD, Neurosciences, University Pierre and Marie Curie, Paris VI – Laboratory of Neurobiology and Molecular Pharmacology, INSERM U109 - 573

#### 1999 - 2000

Master of Advanced Studies (MAS), clinical and experimental pharmacology, Paris Sud XI University

#### 1996 - 1999

Normalien (Student at Ecole Normale Supérieure de Cachan): MSc, MAS : Molecular and Chemical Physic

### 1994 - 1996

BA : Mathematics, Physics, Chemistry.  
Preparatory school for french Grande Ecole

### Industry background

#### 2010-Present

Scientific Alliances Manager at Institut Roche: responsible to establish and manage private/public R&D and translational research partnership between key academic or biotech teams and Genentech R&D in focused diseases therapeutic areas: neuroscience and ophthalmology e.g. neurology, psychiatry, peripheral nervous system, pain, ophthalmology. Responsible for ensuring the follow-up R&D collaborative project and for the identification of innovative opportunities for partnering (licensing-in).

#### 2013 - 2014

Research & Development Project Team Leader at Pierre Fabre Development center

#### 2011 - 2013

Senior Research Scientist & Research Project Team Leader at Pierre Fabre research Institute

#### 2007 - 2009

Research Scientist & Research Project Team Leader at Pierre Fabre research Institute

#### 2006 - 2008

Research Scientist at Pierre Fabre Research Institute

### Areas of research interest

During my positions in academic and industrial R&D was involved in both basic and applied research for the discovery of molecular basis underlying neuropsychiatric diseases, and pain e.g. Parkinson's disease, schizophrenia, addiction, depression, chronic pain.

My interests are to deeply study and understand basic science for the identification and validation of innovative targets, and subsequently drug discovery program from hits to candidates through close interactions with medicinal chemists, early development, and in early clinical development Ph1 and 2.  
I'm currently in charge of scientific partnership and partnering at Roche France, in particular those involving Genentech, in neurosciences, ophthalmology and rare diseases with inter-disciplinary approaches: e.g. genetics, immunology, neuro-protection, pharmacology, etc.

### Contact

Ludovic LERICHE

Address: 30 cours de l'Île Seguin 92650 Boulogne Billancourt cedex 6

Mail : [ludovic.leriche@roche.com](mailto:ludovic.leriche@roche.com)



**Myriam LY LE MOAL**  
Scientific Project Manager

#### Training and academic background 2008 - 2013

PhD Neurosciences & Management - Université Pierre et Marie Curie / Collège des Ingénieurs, Paris

#### 2006 - 2008

Degree Journalism and Scientific Communication - Université Denis Diderot, Paris

#### 1996-2008

Degree Integrative Biology & Physiology option Neurosciences - Université Pierre et Marie Curie, Paris

#### Industry background Present

Scientific Project Manager - Roche, Paris

#### 2013-2015

Senior Grant Manager, Collaborative research - Institut Pasteur, Paris

#### 2013-2015

Research engineer & Project Coordinator, ARS / Inserm, Paris

#### 2008-2013

R & D Project Manager in neurosciences (PhD) - ICM, Paris

#### Areas of research interest

Basic, clinical and biomarker research in neuroscience, ophthalmology and rare diseases, from novel approaches to clinical diagnosis, molecular mechanisms or new technologies showing potential to shift established concepts or paradigms.

Diseases overview: Alzheimer's Disease (AD), Autism/Fragile X, Bipolar Disorder, Depression, Down Syndrome, Eating Disorders, Huntington's Disease, Parkinson's Disease (PD), Spinal Muscular Atrophy (SMA),...

#### Contact

Myriam LY LE MOAL  
Address: 30 cours de l'Île Seguin 92650  
Boulogne Billancourt cedex 6  
Mail: myriam.ly-le\_moal@roche.com



Company name: **SANOFI**

Company size: **over 110 000 employees**

R&D staff: **over 16 000 employees**

Number of countries: **over 100**

Annual sales 2015: **37 billion**

R&D investment: **5.2 billion**

### COMPANY DESCRIPTION

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of health care with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

Our ambition is based on four key strategic priorities: becoming a global healthcare leader with synergistic platforms, bringing innovative products to the market, seizing value-enhancing growth opportunities and adapting our company to future challenges and opportunities. With more than 110,000 employees in 100 countries, Sanofi and its partners act to protect health, enhance life and respond to the potential healthcare needs of the 7 billion people around the world.

For more information: [www.sanofi.com](http://www.sanofi.com) - [www.sanofi.tv](http://www.sanofi.tv)

Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more details please visit our website [www.sanofi.com](http://www.sanofi.com).

### HISTORY OF COMMITMENT

We are committed to becoming a long term partner to the Multiple Sclerosis community by working to deliver scientific advancements that will have a significant impact on the lives of people living with MS.

Alzheimer's and Parkinson's diseases are the two most frequent neurodegenerative diseases. They affect approximately 27 million people worldwide, heavily impacting patients' and caregivers' lives and gradually lead to a loss of autonomy. The medical needs are still major, in particular, due to the absence of treatments preventing or slowing down the disease.

The ambition of our Research is to contribute to fighting these disabling diseases, in particular by preventing or delaying the disease progression, and to deliver innovative and high medical value solutions to patients.

### PRODUCT PORTFOLIO IN THE AREA

- Aubagio® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS).
- Lemtrada® (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).
- Riluzole (Rilutek, Teglutik) is used to slow the progress of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

### PROSPECTIVE IN THIS AREA: THEMATIC PRIORITIES

- GLD52 (anti-CD52 mAb) - Relapsing multiple sclerosis (Phase I)
- Anti-protofibrillar AB mAb - Alzheimer's disease (Phase I)

### SANOFI GENZYME

Sanofi Genzyme exists in France since 1994 and counts over 400 employees in total. The headquarters are situated in Saint Germain en Laye (78), with teams throughout the French regions including activities in French overseas territories and in Lyon at the Polyclonal bioproduction site.

The plant is in the Gerland district in Lyon, the world renowned biotech cluster. The site produces polyclonal antibodies preventing organ rejection in transplanted patients. This product is exclusively produced by Sanofi Genzyme in Lyon and is available in 68 countries worldwide.



**Dominique LESUISSE**  
Lead Generation

#### Training and academic background

Dominique received a B.Sc. and a Ph.D. in Organic Chemistry from the University of Louvain, Belgium in the lab of Léon Ghosez. She then spent 2 years at the University of Irvine, California in Larry Overman's lab and 2 years at MIT in Glenn Berchtold's lab as a postdoctoral fellow.

#### Industry background

Dominique joined in 1987 a French Pharmaceutical company named Roussel-Uclaf. This was repeatedly merged to become successively Hoechst-Roussel, Hoechst-Marion-Roussel, Aventis, Sanofi-Aventis and presently Sanofi. She has been managing Medicinal Chemistry departments in the different Company organizations. She is presently heading a cluster on blood brain barrier within the Neurosciences Therapeutic department.

#### Areas of research interest

Medicinal chemistry and drug design to blood brain barrier with in particular enhancement of biotherapeutics brain exposure.



**François BESNARD**  
External Innovation – Direction Strategy Science policy & External Innovation

#### Training and academic background

PhD degrees in Neurobiology and Molecular Biology from Louis Pasteur University (1988).

#### Industry background

After his PhD, he completed a post doc at the NIH (Bethesda) as a research fellow and then visiting

scientist on transcriptional regulation of an astrocyte specific gene GFAP.

He has more than 20 years of experience in pharmaceutical research in a wide range of diseases, including neurodegenerative diseases, obesity and oncology. He published more than 50 papers in peer-reviewed journals.

During his career in industry, since 1992, François held several managerial positions of increasing responsibility in Synthelabo and Sanofi.

Research organizations, where he alternated roles in Biotechnologies : Molecular biology, functional genomics and molecular genomics support to medicinal chemistry programs and in the development of a biopharmaceutical portfolio.

Since 2010 his activity is focused on identification, evaluation and negotiation of external opportunities; seeking collaborations and compounds in licensing for neurodegenerative diseases.

#### Areas of research interest

Neurobiology : ion channel ; neurodegenerative diseases ; Alzheimer ; Parkinson.



**Jean GODIN**  
Head of Global MS medical affairs Franchise strategy

#### Training and academic background

Jean Godin holds a Doctorate in Medicine (MD) from the University of Montreal, a post Graduate diploma in Family Medicine from the University of Montreal, a MBA in Business Administration from McGill University and is a licensed physician of the Quebec College of Physician & Medical Council of Canada (LMCC).

He practiced medicine full time in the Montreal area in both university and community hospitals until he joined the pharmaceutical industry in December of 1999.

Jean headed scientific affairs in Canada at Teva Pharmaceuticals (innovative division) from 1999 to 2007. In June 2007, he became General Manager for the branded activities of Teva in Canada; he was then responsible for the development and commercialization of the innovative portfolio.

In July 2012, Jean joined Novartis Canada in the position of Chief Scientific Officer and Vice-President, Clinical and Regulatory Affairs, reporting to the CEO. In that role, he was responsible for medical affairs, regulatory affairs, clinical research, health management, drug safety, medical communications, new product planning and scientific operations. Jean and his team worked across several therapeutic areas His team brought to market 5 new chemical entities and obtained additional indications for already approved products.

Jean has also been a member of the Boards of Directors for BIOQuebec, a biotechnology and life science industry association representing more than 150 member companies and R&D centers in Quebec. He was also on the board of the Quebec Network for Personalized Health Care. Since he joined the industry, Jean has kept a part time medical practice.

Jean joined Sanofi Genzyme on May 16, 2016 in the role of Head, Global MS Medical Affairs Franchise Strategy / Tactics and Product Development and is a member of her MS Franchise Medical Affairs Leadership team. He currently lives in Cambridge, Massachusetts.

#### Contact

Jean GODIN  
Mail: [jean.godin@genzyme.com](mailto:jean.godin@genzyme.com)



**Christian DELEUZE**  
President Sanofi Genzyme France and Genzyme Polyclonals

#### Training and academic background

Christian Deleuze is currently the President of Sanofi Genzyme France and Genzyme Polyclonals, part of the Sanofi Group. He joined the company in 2010 and leads the company's strategic planning in line with the global Sanofi Genzyme mission, ensuring patients are provided with treatments, driven by cutting-edge science and a commitment to treating unmet medical needs in Rare Diseases, Multiple Sclerosis and recently Oncology and Immunology.

He obtained his medical degree from, Lariboisière Saint-Louis in Paris and graduated from the ESSEC Business & Management School in the early 90's. He began his professional pharmaceutical career at Bayer Pharma, and from there went on to hold different positions at Searl, Pharmacia and Pfizer where he was Marketing Director and responsible for the launch of Celebrex, in charge of strategy and tactics for branding and global positioning.

In 2003 he created the French subsidiary of Sankyo Pharma, which became Daiichi Sankyo France. In his role as President and founder, from 2003 to 2010, he positioned France as the European leader for the Japanese group, with 500 employees.

Today Christian is also President of the Rare Disease Committee at the LEEM (the French pharma syndicate), where he sits on the board and is a member of both the Administration Committee and the Biotechnology Committee. The LEEM Rare disease group unites the rare disease community; pharmaceutical companies, association representatives and health institutions dedicated to the orphan disease cause.

#### Contact

Christian DELEUZE  
Mail: christian.deleuze@genzyme.com



#### Philippe TRUFFINET

*Clinical Development – Sanofi-Genzyme R&D, MS, Neurology & Ophthalmology*

#### Training and academic background

After his Medicine Residency in Paris, Philippe joined Pharmaceutical Industry in 1989. During his career, he has held several managerial positions of increasing responsibility at Ciba-Geigy, Rhône-Poulenc Rorer, Aventis and Sanofi.

He has more than 20 years of experience in clinical development in a wide range of CNS diseases,

including Multiple Sclerosis, Alzheimer's and Parkinson's disease, Amyotrophic Lateral Sclerosis, Schizophrenia. In the past years, he lead the clinical development of teriflunomide in Multiple Sclerosis. He published more than 20 papers in peer-reviewed journals.

In parallel, Philippe was Consultant in Psychiatry at Hospital La Salpêtrière until 2010.

#### Contact

Philippe Truffinet  
Mail: philippe.truffinet@sanofi.com



#### Jaap de-BOER

*Director Scientific Development Europe*

#### Training and academic background

Jaap de Boer has a medical degree at Erasmus University, Rotterdam. First, he worked as a physician in several hospitals in Rotterdam.

In 1989 he joined Duphar/Solvay Pharma leading up to the position of Marketing Sales Director in Hungary. From 1999 to 2006 he worked for Organon as General Manager in Taiwan and HR in Oss among other things, setting up the medical marketing curriculum and tools for the sales excellence program. In 2006 Jaap joined Genzyme as Medical Director where at that time much emphasis was on the launch and market access to Myozyme®, an enzyme therapy in the field of rare genetic diseases.

Since 2011 he is back on the business side. As Business Unit Director, where although Genzyme was in transition due to a takeover by sanofi, the sales results in the Netherlands are considered best of the world combining highest growth rate and market share. Leadership and strategy are the bases for this success.

Since 2012 he was responsible for the development of a new business unit for the Benelux in the highly competitive multiple sclerosis market, both Genzyme products have

successfully been launched in the Benelux. Aubagio as a first line oral therapy and Lemtrada a transformative treatment with the ability to bring MS into remission.

Since 2015 Jaap has been assigned the function of Director Scientific Development where he advises the commercial organization on scientific developments and opportunities, where he can fully utilize his scientific and his commercial acumen.

#### Contact

Jaap de-BOER  
Mail: jaap.deboer@genzyme.com





## The Hub Bpifrance

En avril 2015, Bpifrance lance Le Hub pour connecter entreprises traditionnelles et innovantes, et accélérer la croissance économique française.

Fort d'une année d'expérience, Le Hub s'est imposé comme la plateforme de connexion Bpifrance entre économie traditionnelle et innovation, grands groupes et startups. Le Hub c'est aujourd'hui 40 des meilleures startups françaises en hyper croissance, sélectionnées et accompagnées sur 12 mois, avec déjà 100 mises en relation et 18 partenariats business créés entre grands comptes et entreprises innovantes. C'est aussi plus de 400 événements business accueillis et organisés dans un espace dédié au centre de Paris.

## The Hub Bpifrance

Early 2015, Bpifrance launched Le Hub – a connector to catalyze business relations between startups, and mid- and large corporations. The team offers a top-quality service of startups sourcing to mid and large corporations, and a post-acceleration program to help boost 40 selected startups for one year. As of today, 400 events were organized in the Hub networking space, more than 100 connections were materialized between startups and corporates and more than 18 partnerships created. Located in the heart of Paris, the Hub is at the crossroads between the business district and the « Silicon Sentier ».



58, boulevard Gouvion-Saint-Cyr  
CS 70073 - 75 858 Paris Cedex 17  
T. : 33 (0)1 45 03 88 88

 [facebook.com/lemedicamentetmoi](https://facebook.com/lemedicamentetmoi)  [@LeemFrance](https://twitter.com/LeemFrance)

 [Leem](https://in.leem.org)  [LeemFrance](https://p.leem.org)

[www.leem.org](http://www.leem.org)

# bpifrance

27-31, avenue du Général Leclerc  
94 710 Maisons-Alfort Cedex

 [facebook.com/bpifrance](https://facebook.com/bpifrance)  [@bpifrance](https://twitter.com/bpifrance)

 [Bpifrance](https://in.bpifrance.fr)

[www.bpifrance.fr](http://www.bpifrance.fr)